CN110317179B - 类赤霉素化合物、其制备方法、药物组合物及应用及其中间体 - Google Patents
类赤霉素化合物、其制备方法、药物组合物及应用及其中间体 Download PDFInfo
- Publication number
- CN110317179B CN110317179B CN201810273045.4A CN201810273045A CN110317179B CN 110317179 B CN110317179 B CN 110317179B CN 201810273045 A CN201810273045 A CN 201810273045A CN 110317179 B CN110317179 B CN 110317179B
- Authority
- CN
- China
- Prior art keywords
- compound
- nmr
- preparation
- cdcl
- gibberellin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 146
- 150000001875 compounds Chemical class 0.000 title claims abstract description 101
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 6
- 150000002367 halogens Chemical class 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 27
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- -1 C 1 -C 6 Alkyl Inorganic materials 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 230000003287 optical effect Effects 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 14
- 238000006352 cycloaddition reaction Methods 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 229940041181 antineoplastic drug Drugs 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 230000000259 anti-tumor effect Effects 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 abstract description 11
- 238000000338 in vitro Methods 0.000 abstract description 6
- 206010009944 Colon cancer Diseases 0.000 abstract description 4
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 4
- 230000005918 in vitro anti-tumor Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 264
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 187
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 130
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 124
- 239000007787 solid Substances 0.000 description 80
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 76
- 238000004440 column chromatography Methods 0.000 description 69
- 239000003208 petroleum Substances 0.000 description 65
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
- 238000002844 melting Methods 0.000 description 61
- 230000008018 melting Effects 0.000 description 61
- 238000006243 chemical reaction Methods 0.000 description 58
- 239000012074 organic phase Substances 0.000 description 51
- 239000012043 crude product Substances 0.000 description 33
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 28
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 28
- 238000001704 evaporation Methods 0.000 description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 23
- 238000003786 synthesis reaction Methods 0.000 description 23
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 22
- 238000001035 drying Methods 0.000 description 22
- 238000005406 washing Methods 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
- 125000001072 heteroaryl group Chemical group 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- 239000005457 ice water Substances 0.000 description 17
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 12
- 239000012453 solvate Substances 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- 239000008346 aqueous phase Substances 0.000 description 10
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 description 10
- IXORZMNAPKEEDV-OBDJNFEBSA-N gibberellin A3 Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)[C@H]1C(O)=O)C[C@H]2[C@]2(C=C[C@@H]3O)[C@H]1[C@]3(C)C(=O)O2 IXORZMNAPKEEDV-OBDJNFEBSA-N 0.000 description 10
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 235000010378 sodium ascorbate Nutrition 0.000 description 9
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 9
- 229960005055 sodium ascorbate Drugs 0.000 description 9
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 9
- LFZJRTMTKGYJRS-UHFFFAOYSA-N 1-chloro-4-ethynylbenzene Chemical group ClC1=CC=C(C#C)C=C1 LFZJRTMTKGYJRS-UHFFFAOYSA-N 0.000 description 8
- XTKBMZQCDBHHKY-UHFFFAOYSA-N 1-ethynyl-4-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC=C(C#C)C=C1 XTKBMZQCDBHHKY-UHFFFAOYSA-N 0.000 description 8
- KBIAVTUACPKPFJ-UHFFFAOYSA-N 1-ethynyl-4-methoxybenzene Chemical group COC1=CC=C(C#C)C=C1 KBIAVTUACPKPFJ-UHFFFAOYSA-N 0.000 description 8
- NHUBNHMFXQNNMV-UHFFFAOYSA-N 2-ethynylpyridine Chemical compound C#CC1=CC=CC=N1 NHUBNHMFXQNNMV-UHFFFAOYSA-N 0.000 description 8
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- KSZVOXHGCKKOLL-UHFFFAOYSA-N 4-Ethynyltoluene Chemical group CC1=CC=C(C#C)C=C1 KSZVOXHGCKKOLL-UHFFFAOYSA-N 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000012280 lithium aluminium hydride Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 150000004677 hydrates Chemical class 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- LTLVZQZDXQWLHU-UHFFFAOYSA-N 1-bromo-4-ethynylbenzene Chemical group BrC1=CC=C(C#C)C=C1 LTLVZQZDXQWLHU-UHFFFAOYSA-N 0.000 description 6
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 6
- 239000005980 Gibberellic acid Substances 0.000 description 6
- 150000001540 azides Chemical class 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 5
- 229940126657 Compound 17 Drugs 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 5
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 5
- 229940125810 compound 20 Drugs 0.000 description 5
- 229940126086 compound 21 Drugs 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 4
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 4
- 229930191978 Gibberellin Natural products 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 4
- 229940125961 compound 24 Drugs 0.000 description 4
- 229940125846 compound 25 Drugs 0.000 description 4
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 4
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003448 gibberellin Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 3
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 3
- QXSWHQGIEKUBAS-UHFFFAOYSA-N 1-ethynyl-4-fluorobenzene Chemical group FC1=CC=C(C#C)C=C1 QXSWHQGIEKUBAS-UHFFFAOYSA-N 0.000 description 3
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical class C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 3
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 3
- HIYWOHBEPVGIQN-UHFFFAOYSA-N 1h-benzo[g]indole Chemical class C1=CC=CC2=C(NC=C3)C3=CC=C21 HIYWOHBEPVGIQN-UHFFFAOYSA-N 0.000 description 3
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 3
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 3
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical group C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 3
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 3
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 3
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
- 238000005899 aromatization reaction Methods 0.000 description 3
- 150000001556 benzimidazoles Chemical class 0.000 description 3
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 3
- XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940126208 compound 22 Drugs 0.000 description 3
- 229940125833 compound 23 Drugs 0.000 description 3
- 229940125851 compound 27 Drugs 0.000 description 3
- 229940127204 compound 29 Drugs 0.000 description 3
- 150000002240 furans Chemical class 0.000 description 3
- 150000002460 imidazoles Chemical class 0.000 description 3
- AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 3
- 150000002537 isoquinolines Chemical class 0.000 description 3
- 150000002545 isoxazoles Chemical class 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 150000002916 oxazoles Chemical class 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003216 pyrazines Chemical class 0.000 description 3
- 150000003217 pyrazoles Chemical class 0.000 description 3
- 150000004892 pyridazines Chemical class 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 150000003222 pyridines Chemical class 0.000 description 3
- 150000003230 pyrimidines Chemical class 0.000 description 3
- 150000003233 pyrroles Chemical class 0.000 description 3
- 150000003248 quinolines Chemical class 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 150000003557 thiazoles Chemical class 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- 150000003577 thiophenes Chemical class 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- RGPBQGGBWIMGMA-BJMVGYQFSA-N 5-[(e)-[5-(4-bromophenyl)-6-hydroxy-3,6-dihydro-1,3,4-oxadiazin-2-ylidene]methyl]-1h-pyrimidine-2,4-dione Chemical compound OC1O\C(=C\C=2C(NC(=O)NC=2)=O)NN=C1C1=CC=C(Br)C=C1 RGPBQGGBWIMGMA-BJMVGYQFSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 150000003459 sulfonic acid esters Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- VEPTXBCIDSFGBF-UHFFFAOYSA-M tetrabutylazanium;fluoride;trihydrate Chemical compound O.O.O.[F-].CCCC[N+](CCCC)(CCCC)CCCC VEPTXBCIDSFGBF-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- IVHKZCSZELZKSJ-UHFFFAOYSA-N 2-hydroxyethyl sulfonate Chemical compound OCCOS(=O)=O IVHKZCSZELZKSJ-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- XUINISXRACTVNW-UHFFFAOYSA-N 9,10-dioxoanthracene-2-sulfonic acid;sodium Chemical compound [Na].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 XUINISXRACTVNW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229910014265 BrCl Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CODNYICXDISAEA-UHFFFAOYSA-N bromine monochloride Chemical compound BrCl CODNYICXDISAEA-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-M sodium 2-anthraquinonesulfonate Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)[O-])=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N tert-butyl alcohol Substances CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229930002348 tetracyclic diterpenoid Natural products 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C247/00—Compounds containing azido groups
- C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
- C07C247/08—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated
- C07C247/10—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/86—Ring systems containing bridged rings containing four rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种类赤霉素化合物、其制备方法、药物组合物、应用及其中间体,所述如式I所示的类赤霉素化合物具有较好的体外抗肿癌细胞毒活性,尤其对于乳腺癌细胞或结肠癌细胞具有显著的体外细胞毒活性。
Description
技术领域
本发明涉及类赤霉素化合物、其制备方法、药物组合物及应用及其中间体。
背景技术
癌症通常也叫恶性肿瘤,是严重威胁人类健康和生命的主要疾病之一,已成为危害人类健康的“第二杀手”(仅次于心血管疾病)。癌症作为一种全身性疾病,药物治疗是一种非常重要的治疗方法,但是目前常用的化疗药物多数具有大的副作用,抗瘤谱狭窄,从而限制了其应用。
例如,赤霉素是一类具有多种生物活性的四环二萜类化合物,广泛存在于微生物和植物体内,作为具有生物活性的基团表现出很强的抗癌活性。但是,目前还没有发现赤霉素类抗癌药物。
因此,寻找特异性高、毒副作用低甚至无毒的抗癌药物已成为药物研究中十分重要的课题。
发明内容
本发明所要解决的技术问题是为了克服现有技术中目前治疗癌症的药物多数具有副作用、抗瘤谱狭窄、从而限制其应用的问题,因而提供了一种类赤霉素化合物、其制备方法、药物组合物、应用及其中间体。本发明提供的类赤霉素化合物具有较好的体外抗肿癌细胞毒活性,尤其对于乳腺癌细胞或结肠癌即系具有显著的体外细胞毒活性。
本发明是通过下述技术方案来解决上述技术问题的。
本发明提供了一种如式I所示的类赤霉素化合物、其互变异构体、光学异构体、水合物、溶剂化物、多晶型物、药学上可接受的盐、药学上可接受的前体药物或衍生物:
其中,R1为H或卤素;
R2为H、OH或OTs(Ts为对甲苯磺酰基);
R3为甲基;
R6为H或O;
当中代表单键时,R4为H;R5为取代或未取代的C6-C20的芳基,或取代或未取代的C2-C20的杂芳基;所述取代或未取代的C6-C20的芳基,或取代或未取代的C2-C20的杂芳基中的取代基为其中X选自C,N,S或O(例如C或N);R为H、卤素、C1-C6的烷基、卤素取代的C1-C6的烷基,或C1-C6的烷氧基;n为1-5的整数;
R7为CH2或O;
R8为OH、C1-C6的烷基或C1-C6的烷氧基;
且所述是式I所示的化合物不为如下任一结构所示的化合物:
本发明中,所述取代或未取代的C6-C20的芳基可为取代或未取代的C6-C10的芳基,例如取代或未取代的苯基,或取代或未取代的萘基。
本发明中,所述取代或未取代的C2-C20的杂芳基可为含有一个或多个(例如两个)芳杂环,杂原子为N、S或O(例如N);所述杂原子的个数为1个或多个(例如2或3)的杂芳基,例如所述取代或未取代的C2-C20的杂芳基为含有一个芳杂环,杂原子为氮,所述杂原子的个数为1-3个的取代或未取代的C2-C10的杂芳基(例如为取代或未取代的吡咯,取代或未取代的呋喃,取代或未取代的噻吩,取代或未取代的吡唑,取代或未取代的咪唑,取代或未取代的噁唑,取代或未取代的噻唑,取代或未取代的异噁唑,取代或未取代的吡啶,取代或未取代的哒嗪,取代或未取代的嘧啶,取代或未取代的吡嗪、取代或未取代的1,2,4三氮唑或者取代或未取代的1,2,3三氮唑再例如所述取代或未取代的C2-C20的杂芳基为含有2个环的稠合芳杂基(例如取代或未取代的苯并吲哚,取代或未取代的苯并咪唑,取代或未取代的喹啉,取代或未取代的异喹啉。)
本发明中,所述卤素可为氟、氯、溴或碘,例如溴。
本发明中,所述C1-C6的烷基可为C1-C4的烷基,例如甲基,乙基,丙基,异丙基和正丁基。
本发明中,所述卤素取代的C1-C6的烷基中的卤素取代基的个数可为一个或多个(2个或三个);所述卤素可为氟。
本发明中,所述C1-C6的烷氧基可为C1-C4的烷氧基,例如甲氧基,乙氧基和丙氧基。
本发明中,所述式I所示的化合物可选自如下式II、式III、式IV或式V所示的化合物中的任一种:
R12为C1-C6的烷基;
R1、R2、X、R和C1-C6的烷基的定义均如前所述。
较佳地,所述式II所示化合物中:
当所述R1为卤素时,所述R为卤素,或者卤素取代的C1-C6的烷基(例如-CF3);
当所述R1为H,所述R为卤素取代的C1-C6的烷基(例如-CF3)。
较佳地,所述式II所示的化合物中,所述R2为OH。
所述式II所示的化合物的结构可为:
各取代基定义如前所述。
所述式III所示化合物中,所述R1可为氢或卤素,例如氢。
所述式III所示化合物中,所述R2可OH或OTs,优选OH。
所述式III所示的化合物的结构可为:
各取代基定义如前所述。
所述式IV所示的化合物中,所述R1可为氢。
所述式IV所示的化合物中,所述R2可为OH或OTs。
所述式IV所示的化合物的结构可为:
各取代基定义如前所述。
所述式V所示的化合物中,所述R1可为卤素,例如氟。
所述式V所示的化合物中,所述R1可为OH或OTs。
所述式V所示的化合物中,所述R12可为甲基。
R20和R21各自独立地为甲基;其余各取代基定义如前所述。
在本发明一优选实施方式中,所述式I所示的类赤霉素化合物、其互变异构体、光学异构体、水合物、溶剂化物、多晶型物、药学上可接受的盐、药学上可接受的前体药物或衍生物中,
所述R1为H或卤素;
所述R2为H、OH或OTs;
所述R3为甲基;
当所述中代表单键时,R4为H;R5为取代或未取代的C6-C20的芳基,或取代或未取代的C2-C20的杂芳基;所述取代或未取代的C6-C20的芳基,和取代或未取代的C2-C20的杂芳基中的取代基为其中X选自C,N,S或O(例如C或N);R选自H、卤素、C1-C6的烷基、卤素取代的C1-C6的烷基或C1-C6的烷氧基;n为1;
R7为CH2或O;
在本发明一优选实施方式中,所述式I所示的类赤霉素化合物、其互变异构体、光学异构体、水合物、溶剂化物、多晶型物、药学上可接受的盐、药学上可接受的前体药物或衍生物中,所述取代或未取代的C6-C20的芳基为取代或未取代的C6-C10的芳基;所述取代或未取代的C2-C20的杂芳基为含有一个芳杂环,杂原子为氮,所述杂原子的个数为1-3个的取代或未取代的C2-C10的杂芳基,或者所述取代或未取代的C2-C20的杂芳基为含有2个环的稠合芳杂基;所述为 其他各基团及取代基定义如前所述。
在本发明一优选实施方式中,所述式I所示的类赤霉素化合物、其互变异构体、光学异构体、水合物、溶剂化物、多晶型物、药学上可接受的盐、药学上可接受的前体药物或衍生物中,所述取代或未取代的C6-C20的芳基为取代或未取代的C6-C10的芳基;所述取代或未取代的C2-C20的杂芳基为含有一个芳杂环,杂原子为氮,所述杂原子的个数为1-3个的取代或未取代的C2-C10的杂芳基,或者所述取代或未取代的C2-C20的杂芳基为含有2个环的稠合芳杂基;所述为 所述为所述为所述为其他各基团定义如前所述。
在本发明一优选实施方式中,所述式I所示的类赤霉素化合物、其互变异构体、光学异构体、水合物、溶剂化物、多晶型物、药学上可接受的盐、药学上可接受的前体药物或衍生物中,所述取代或未取代的C6-C20的芳基为取代或未取代的苯基,或取代或未取代的萘基;所述取代或未取代的C2-C20的杂芳基为取代或未取代的吡咯,取代或未取代的呋喃,取代或未取代的噻吩,取代或未取代的吡唑,取代或未取代的咪唑,取代或未取代的噁唑,取代或未取代的噻唑,取代或未取代的异噁唑,取代或未取代的吡啶,取代或未取代的哒嗪,取代或未取代的嘧啶,取代或未取代的吡嗪、取代或未取代的1,2,4三氮唑取代或未取代的1,2,3三氮唑取代或未取代的苯并吲哚,取代或未取代的苯并咪唑,取代或未取代的喹啉,或取代或未取代的异喹啉;所述R8为OH或C1-C6的烷氧基时,所述为所述R8为C1-C6的烷基时,所述为其他各基团定义如前所述。
在本发明一优选实施方式中,所述式I所示的类赤霉素化合物、其互变异构体、光学异构体、水合物、溶剂化物、多晶型物、药学上可接受的盐、药学上可接受的前体药物或衍生物中,所述取代或未取代的C6-C20的芳基为取代或未取代的苯基,或取代或未取代的萘基;所述取代或未取代的C2-C20的杂芳基为取代或未取代的吡咯,取代或未取代的呋喃,取代或未取代的噻吩,取代或未取代的吡唑,取代或未取代的咪唑,取代或未取代的噁唑,取代或未取代的噻唑,取代或未取代的异噁唑,取代或未取代的吡啶,取代或未取代的哒嗪,取代或未取代的嘧啶,取代或未取代的吡嗪、取代或未取代的1,2,4三氮唑取代或未取代的1,2,3三氮唑取代或未取代的苯并吲哚,取代或未取代的苯并咪唑,取代或未取代的喹啉,或取代或未取代的异喹啉;所述为所述为所述为所述为其他各基团定义如前所述。
本发明中,所述式II所示的化合物可选自下列任一化合物:
本发明中,所述式III所示的化合物可选自下列任一化合物:
本发明中,所述式IV所示的化合物可选自下列任一化合物:
本发明中,所述式V所示的化合物可选自下列任一化合物:
本发明还提供了一种如式I所示的赤霉素衍生物制备方法,其包括以下步骤:
方法1:在铜的催化作用下,将式VI所示的化合物式VII所示的化合物进行环加成反应,得到式I所示化合物即可;
或方法2:
各取代基定义如前所述。
所述方法1中,所述环加成反应的操作及方法可参考本领域的常规操作及方法;例如参照V.V.Rostovtsev,L.G.Green,V.V.Fokin and K.B.Sharpless,Angewandte Chemie,2002,41,2596-2599记载的操作及方法。
例如,制备路线1:
本发明一优选实施方式中,以赤霉素(GA3)为原料,与硫酸二甲酯、碳酸钾和丙酮反应合成赤霉素(GA3)甲酯,经过戴斯-马丁氧化得到羰基赤霉素甲酯,(具体操作可参考J.Chen,Z.Sun,Y.Zhang,X.Zeng,C.Qing,J.Liu,L.Li and H.Zhang,Bioorganic&medicinal chemistry letters,2009,19,5496-5499);然后与四三苯基膦钯、蒽醌-2-磺酸钠、二甲亚砜和水,在80℃反应12h得到芳构化产物,(具体操作可参考J.R.Annand,P.A.Bruno,A.K.Mapp and C.S.Schindler,Chemical communications,2015,51,8990-8993),四氢铝锂还原芳构化产物并用对甲苯磺酰氯保护伯羟基得到磺酸酯化合物,用叠氮化钠和N,N-二甲基甲酰胺在80℃下反应3h得到叠氮化合物,最后在抗坏血酸钠、醋酸铜、四氢呋喃和水的作用下,发生铜催化的叠氮-炔基Husigen环加成反应制备化合物C1-C8。例如,制备路线2:
本发明一优选实施方式中,以赤霉素(GA3)为原料,与1.2M盐酸,在65℃下反应2.5h得到芳构化产物,在硫酸二甲酯、碳酸钾和丙酮的作用下得到芳构化的赤霉素(GA3)甲酯化合物,通过四氢铝锂还原酯基和对甲苯磺酰氯保护伯羟基得到磺酸酯化合物,用叠氮化钠将磺酸酯叠氮化,最后经过铜催化的叠氮-炔基Husigen环加成反应制备化合物C9-C16。(具体操作可参考R.W.Huigens,3rd,K.C.Morrison,R.W.Hicklin,T.A.Flood,Jr.,M.F.Richter and P.J.Hergenrother,Nature chemistry,2013,5,195-202;和V.V.Rostovtsev,L.G.Green,V.V.Fokin and K.B.Sharpless,Angewandte Chemie,2002,41,2596-2599。)
例如,制备路线3:
本发明一优选实施方式中,合合成的芳构化产物8,用叔丁基二甲基氯硅烷保护酚羟基,四氢铝锂还原酯基,对甲苯磺酰氯保护伯羟基,四正丁基氟化胺脱去叔丁基二甲基硅醚保护,叠氮化钠将磺酸酯叠氮化,最后经过铜催化的叠氮-炔基Husigen环加成反应制备化合物C17-C24。
例如,制备路线4:
本发明一优选实施方式中,合成的叠氮化合物21与N-溴代丁二酰亚胺、二异丙基胺和二氯甲烷反应得到溴代化合物,再经过铜催化的叠氮-炔基Husigen环加成反应制备化合物C25-C31。
例如,制备路线5:
本发明一优选实施方式中,合成的磺酸酯化合物10与二氧化硒、过氧叔丁醇和二氯甲烷反应得到烯丙醇化合物23和含酮化合物24;烯丙醇化合物经叠氮化反应得到叠氮化合物25,再经过铜催化的叠氮-炔基Husigen环加成反应和戴斯-马丁氧化制备化合物C32-C39;同样,化合物24经过叠氮化反应和铜催化的叠氮-炔基Husigen环加成反应制备C48-C55。
例如,制备路线6:
本发明一优选实施方式中,合成硅醚保护的化合物17与过氧叔丁醇、二氧化硒和二氯甲烷反应得到烯丙醇化合物29,用四氢铝锂还原甲酯,对甲苯磺酰氯活化伯羟基,叠氮化钠将磺酸酯转化为叠氮化合物32;叠氮化合物经过铜催化的叠氮-炔基Husigen环加成反应,戴斯-马丁氧化和四正丁基氟化胺脱去叔丁基二甲基硅醚保护得到化合物C40-C47。
例如,制备路线7:
本发明一优选实施方式中,合成的酚类化合物20与二氧化硒、过氧叔丁醇和二氯甲烷反应得到酮化合物27,经过叠氮化反应和铜催化的叠氮-炔基Husigen环加成反应制备C56-C62。
根据本发明公开的上述制备方法,本领域技术人员可采用与之相同的原理和方法,制得本发明的通式化合物II、III、IV或V中涉及的各具体化合物。
本发明还提供了一种药物组合物,其包括治疗有效量的如式I所示的类赤霉素衍生物、其互变异构体、光学异构体、水合物、溶剂化物、多晶型物、药学上可接受的盐、药学上可接受的前体药物或衍生物,和一种或多种药学上可接受的载体或赋形剂。
本发明还提供了如式I所示的类赤霉素衍生物在制备治疗和/或预防抗肿瘤药物中的应用。
所述抗肿瘤药物可为抗乳腺癌药物和/或抗肠癌药物。
本发明还提供了如下所示的式I所示类赤霉素衍生物的中间体:
本发明中,所述的确定了碳数范围的“Cx1-Cy1”的取代基(x1和y1为整数)、如“Cx1-Cy1”烷基、“Cx1-Cy1”的烷氧基、“Cx1-Cy1”芳基或“Cx1-Cy1”杂芳基,均表示未包含取代基的碳数,例如C1-C10烷基表示未包含取代基的C1-C10烷基。
关于任一基团包含一个或多个取代基,本领域一般技术人员均可理解,但不包括不切实际的高位阻、合成上不可行的和/或内在不稳定的取代基。
本发明中,所用的术语“药学上可接受的盐”指药学上可接受的与酸或与碱形成的盐和溶剂化物。这类药学上可接受的盐包括但不限于与无机酸形成的盐,如盐酸盐、磷酸盐、二磷酸盐、氢溴酸盐、硫酸盐、亚磺酸盐、硝酸盐、及其类似盐;也包括与有机酸形成的盐,如苹果酸盐、马来酸盐、富马酸盐、酒石酸盐、琥珀酸盐、柠檬酸盐、醋酸盐、乳酸盐、磺酸盐、对甲苯磺酸盐、2-羟基乙基磺酸盐、苯甲酸盐、水杨酸盐、硬脂酸盐和链烷酸盐如醋酸盐,HOOC-(CH2)n-COOH其中n为0-4的盐,及其类似盐。类似地,药学上可接受的阳离子包括但不限于钠、钾、钙、铝、锂和铵。本领域的成熟技术人员可识别各种可能用来制备无毒的药学上可接受的盐的合成方法。
本发明中,所述的“溶剂化物”如“水合物”,是由溶剂和化合物互相作用形成。术语“化合物”,应该包括了化合物的溶剂化物(包括化合物的水合物)。同样,“盐”也包括了盐的溶剂化物(如盐的水合物)。合适的溶剂化物是药学上可接受的,例如水合物,它包括了单水合物和半水合物。
本发明中,所述的“预防和/或治疗有效剂量”表示(i)预防和/或治疗本申请所述的具体疾病或病症的本发明化合物的量,(ii)削弱、改善或消除本申请所述的具体疾病或病症的一种或多种症状的本发明化合物的量,或(iii)预防或延迟本申请所述的具体疾病或病症的一种或多种症状的发作的本发明化合物的量。
在不违背本领域常识的基础上,上述各优选条件,可任意组合在不违背本领域常识的基础上,上述各优选条件,可任意组合,即得本发明各较佳实例。
本发明所用试剂和原料均市售可得。
本发明的积极进步效果在于:本发明的类赤霉素衍生物具有较好的抗肿瘤活性。
具体实施方式
下面通过实施例的方式进一步说明本发明,但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法,按照常规方法和条件,或按照商品说明书选择。
C1-C8的制备反应式如下:
上述制备方法步骤如下:
化合物5的合成:
将赤霉酸(GA3)(5.19g,15mmol)溶于丙酮(80mL)中,在0℃下加入硫酸二甲酯(1.80g,14.3mmol)和无水碳酸钾(4.14g,30mmol),加完后移除冰水浴,室温反应10h,TLC监测反应完毕后,减压蒸出反应液,加入50mL水,水相用乙酸乙酯(3×100mL)萃取,合并有机相,依次用水(40mL)、饱和食盐水(2×40mL)洗,用无水硫酸钠干燥有机相,减压蒸干得白色固体,即化合物5,5.31g,粗产物未经柱层析直接做下一步反应。
化合物6的合成:
将化合物5(5.31g,14.75mmol)溶于二氯甲烷(140mL)中,缓慢的加入戴斯-马丁氧化剂(6.88g,16.23mmol),室温反应8h,反应完毕后,加入80mL水,碳酸氢钠(4eq),硫代硫酸钠(4eq),搅拌至溶液澄清。用二氯甲烷(3×100mL)萃取,合并有机相,依次用水(2×40mL)和饱和食盐水(2×40mL)洗,用无水硫酸钠干燥有机相,减压蒸干得白色固体即化合物6,4.14g。粗产物未经柱层析直接做下一步反应。
化合物8的合成:
在氮气保护下,将化合物6(4.14g,11.56mmol)、四三苯基膦钯(535mg,0.46mmol)、蒽醌-2-磺酸钠(538mg,1.73mmol)、二甲亚砜(60ml)和水(20ml)混合,在80℃下反应16h,反应毕后,加入60mL水,水相用乙酸乙酯(3×120mL)萃取,合并有机相,依次用水(3×40mL)、饱和食盐水(3×40mL)洗,用无水硫酸钠干燥有机相,减压蒸干,粗产物经柱层析(石油醚/乙酸乙酯=1:1)得白色固体2.31g。从赤霉酸(GA3)为原料合成化合物8的三步总收率为49%。
1H NMR(400MHz,CDCl3)δ:6.77(d,J=7.9Hz,1H),6.62(d,J=7.9Hz,1H),6.16(s,1H),5.17(t,J=2.4Hz,1H),5.02(t,J=1.9Hz,1H),3.66(s,3H),3.62(s,1H),3.33(dd,J=8.4,2.5Hz,1H),2.73(dt,J=16.3,3.0Hz,1H),2.54-2.22(m,2H),2.09(s,3H),2.04(dt,J=6.4,4.1Hz,1H),1.92(ddt,J=15.0,10.3,8.0Hz,1H),1.75(dtd,J=20.0,10.5,9.3,6.5Hz,2H),1.60(dd,J=10.7,2.6Hz,1H),1.56-1.45(m,1H).13C NMR(100MHz,CDCl3)δ:173.08,155.19,152.92,140.97,138.19,121.84,120.09,114.30,106.89,78.78,56.53,54.04,51.95,48.64,47.53,38.57,38.35,21.16,12.27.
化合物9的合成:
在氮气保护下,将化合物8(4.14g,13.18mmol)溶于无水的四氢呋喃(100mL)中,在冰水浴的条件下分批加入四氢铝锂(1.00g,26.36mmol),加完后撤去冰水浴,在室温反应4h,反应结束,缓慢加入40mL冰水,水相用乙酸乙酯(3×110mL)萃取,合并有机相,依次用水(2×30mL)、饱和食盐水(2×30mL)洗,用无水硫酸钠干燥有机相,减压蒸干得白色固体3.53g,粗产物未经柱层析直接做下一步反应。
化合物10的合成:
将化合物9(3.53g,12.34mmol)溶于无水的二氯甲烷(100mL)中,分别加入二异丙基乙胺(3.98g,30.85mmol)、对甲苯磺酰氯(4.92g,25.91mmol)、4-二甲氨基吡啶(301mg,2.47),在室温反应8h,反应结束,减压蒸干,粗产物经柱层析(石油醚/乙酸乙酯=2:1)得白色固体即化合物10,5.25g。两步的总收率为67%。
1H NMR(300MHz,CDCl3)δ:7.77-7.65(m,2H),7.66-7.57(m,2H),7.31(dd,J=10.9,8.1Hz,4H),6.84(s,2H),5.14(d,J=2.4Hz,1H),5.00(s,1H),4.22-3.85(m,2H),3.04(d,J=7.9Hz,1H),2.97(dd,J=7.4,4.5Hz,1H),2.75(dt,J=16.5,2.9Hz,1H),2.43(d,J=8.6Hz,7H),2.21(s,1H),2.14-2.03(m,1H),1.84(s,3H),1.70-1.57(m,2H),1.46(d,J=10.8Hz,1H),1.33(dd,J=10.7,2.6Hz,1H),0.85(dq,J=7.0,3.5,3.0Hz,1H).13C NMR(75MHz,CDCl3)δ:154.76,146.96,145.48,145.00,144.47,142.20,132.84,132.29,129.85,129.76,128.89,128.22,127.65,121.44,120.11,106.90,77.79,67.85,52.98,49.70,48.59,46.73,38.19,37.62,21.64,21.55,20.55,12.65.
化合物11的合成:
将化合物10(5.25g,8.82mmol)和叠氮化钠(1.72g,26.46mmol)溶于无水的N,N-二甲基甲酰胺(80mL)。在氮气保护下,80℃反应4h,反应毕后,加入50mL水,水相用乙酸乙酯(3×130mL)萃取,合并有机相,依次用水(3×40mL)、饱和食盐水(4×40mL)洗,用无水硫酸钠干燥有机相,减压蒸干,粗产品经柱层析(石油醚/乙酸乙酯=3:1)得白色固体即化合物11,3.08g。产率为75%。
1H NMR(400MHz,CDCl3)δ:7.70(d,J=8.0Hz,2H),7.30(d,J=8.0Hz,2H),6.86(t,J=5.6Hz,2H),5.16(t,J=2.3Hz,1H),5.06(s,1H),3.42(dd,J=12.7,7.3Hz,1H),3.35(dd,J=12.6,5.1Hz,1H),3.15(d,J=8.1Hz,1H),2.86(dd,J=7.2,5.2Hz,1H),2.79(dt,J=16.3,3.0Hz,1H),2.51(d,J=2.5Hz,1H),2.44(s,3H),2.17-2.06(m,1H),2.00(s,3H),1.97-1.83(m,2H),1.66(dd,J=10.3,4.5Hz,2H),1.47(d,J=10.8Hz,1H),1.38(dd,J=10.8,2.7Hz,1H).13C NMR(100MHz,CDCl3)δ155.02,147.16,145.41,144.34,144.16,133.00,129.79,128.78,128.46,121.49,120.19,107.06,78.14,53.43,50.60,50.11,48.96,46.84,38.34,37.83,21.78,20.73,12.99。
化合物C1的制备:
将化合物11(50mg,0.11mmol)、苯乙炔(22.4mg,0.22mmol)、醋酸铜(33.0mg,0.17mmol)、抗坏血酸钠(43.6mg,0.22mmol)、四氢呋喃(8mL)和水(2mL)混合,反应5h,反应结束,加入10mL水,水相用乙酸乙酯(3×20mL)萃取,合并有机相,依次用水(2×8mL)、饱和食盐水(2×8mL)洗,用无水硫酸钠干燥有机相,减压蒸干,粗产品经柱层析(石油醚/乙酸乙酯=2:1)得白色固体即化合物C1,38.4mg,收率61%。熔点:109-111℃。
IRνmax(cm-1):3418,2928,2859,1733,1597,1467,1369,1171,1093,814.87,715,553.HRMS(ESI)m/z calculated for C33H34O4N3S[M+H]+:568.2265,found:568.2264.1H NMR(400MHz,CDCl3)δ:7.75(d,J=7.4Hz,2H),7.69(d,J=8.1Hz,2H),7.38(t,J=7.5Hz,2H),7.31(d,J=7.3Hz,1H),7.27-7.24(m,2H),7.23(s,1H),6.83(d,J=8.1Hz,1H),6.77(d,J=8.1Hz,1H),5.16(d,J=2.5Hz,1H),5.06(s,1H),4.62(dd,J=14.2,6.0Hz,1H),4.51(dd,J=14.2,5.8Hz,1H),3.34(t,J=5.9Hz,1H),2.80-2.67(m,2H),2.66-2.56(m,1H),2.43(s,3H),2.05(dt,J=15.2,4.4Hz,2H),1.95-1.81(m,4H),1.64(dt,J=12.7,6.1Hz,2H),1.55(d,J=10.8Hz,1H),1.41(dd,J=10.8,2.6Hz,1H).13C NMR(100MHz,CDCl3)δ:154.54,147.77,147.24,145.42,144.65,143.74,133.23,130.35,129.82,129.21,128.81,128.27,128.18,125.73,121.48,120.61,120.51,107.37,78.06,53.70,50.99,49.49,49.29,46.55,38.23,37.39,21.71,20.71,12.78.
化合物C2的制备:
制备方法同化合物C1,将苯乙炔改成4-溴苯乙炔,得白色固体即化合物C2,41.3mg,收率58%,熔点:118-121℃。
IRνmax(cm-1):3416,2928,2861,1597,1468,1367,1195,1171,1045,834,554.HRMS(ESI)m/z calculated for C33H33O4N3Br S[M+H]+:646.1370,found:[M+H]+646.1372,[M+2+H]+648.1336.1H NMR(400MHz,CDCl3)δ:7.68(d,J=8.2Hz,2H),7.67–7.57(m,2H),7.53–7.43(m,2H),7.31–7.27(m,3H),6.84(d,J=8.1Hz,1H),6.76(d,J=8.1Hz,1H),5.17(t,J=2.3Hz,1H),5.05(d,J=2.4Hz,1H),4.62(dd,J=14.1,5.9Hz,1H),4.48(dd,J=14.2,6.1Hz,1H),3.33(t,J=6.0Hz,1H),2.71(dd,J=18.9,5.1Hz,2H),2.61(dt,J=16.1,2.9Hz,1H),2.44(s,3H),2.24(d,J=3.5Hz,1H),2.07(dd,J=9.2,5.8Hz,1H),1.99–1.87(m,1H),1.87(s,3H),1.64(dd,J=10.8,4.8Hz,2H),1.56(d,J=10.8Hz,1H),1.40(dd,J=10.8,2.6Hz,1H).13C NMR(100MHz,CDCl3)δ:154.48,147.13,146.69,145.56,144.67,143.76,133.14,131.92,129.89,129.34,129.27,128.21,127.30,122.01,121.46,120.92,120.54,107.41,77.98,53.70,50.95,49.55,49.15,46.53,38.27,37.40,21.77,20.69,12.78.
化合物C3的制备:
制备方法同化合物C1,将苯乙炔改成4-甲氧基苯乙炔,得白色固体即化合物C3,42.1mg,收率64%,熔点:112-113℃。
IRνmax(cm-1):3417,2929,1618,1500,1467,1368,1249,1171,1093,836,554.HRMS(ESI)m/z calculated for C34H36O5N3S[M+H]+:598.2370,found:598.2368.1H NMR(400MHz,CDCl3)δ:7.68(ddd,J=8.5,5.2,2.4Hz,4H),7.28(d,J=1.5Hz,2H),7.18(s,1H),6.96–6.86(m,2H),6.84(d,J=8.2Hz,1H),6.78(d,J=8.1Hz,1H),5.16(t,J=2.4Hz,1H),5.04(d,J=2.5Hz,1H),4.59(dd,J=14.1,6.0Hz,1H),4.45(dd,J=14.1,5.9Hz,1H),3.80(s,3H),3.33(t,J=6.0Hz,1H),2.73(d,J=8.5Hz,1H),2.70–2.64(m,1H),2.61(t,J=2.9Hz,1H),2.43(s,3H),2.19(d,J=4.6Hz,1H),2.05(dt,J=9.0,4.2Hz,1H),1.96–1.87(m,1H),1.86(s,3H),1.70–1.60(m,2H),1.55(d,J=10.9Hz,1H),1.39(dd,J=11.1,2.6Hz,1H).13CNMR(100MHz,CDCl3)δ:159.63,154.63,147.62,147.19,145.49,144.69,143.91,133.20,129.87,129.22,128.29,127.06,123.14,121.45,120.50,119.88,114.26,107.34,78.01,55.38,53.73,51.00,49.42,49.22,46.54,38.28,37.39,21.76,20.71,12.75.
化合物C4的制备:
制备方法同化合物C1,将苯乙炔改成2-乙炔基吡啶,经柱层析(石油醚/乙酸乙酯=1:2)得白色固体即化合物C4,33.8mg,收率:54%,熔点:108-122℃。
IRνmax(cm-1):3416,2927,2857,1598,1470,1369,1195,1172,1044,836,784,554.HRMS(ESI)m/z calculated for C32H33O4N4S[M+H]+:569.2217,found:569.2215.1H NMR(400MHz,CDCl3)δ:8.53(dt,J=4.8,1.3Hz,1H),8.14(d,J=7.9Hz,1H),7.83(s,1H),7.80–7.70(m,3H),7.35–7.28(m,2H),7.22(ddd,J=7.6,4.8,1.2Hz,1H),6.87(d,J=8.2Hz,1H),6.82(d,J=8.1Hz,1H),5.13(d,J=2.6Hz,1H),5.01(d,J=2.1Hz,1H),4.60(dd,J=14.2,7.4Hz,1H),4.41(dd,J=14.2,5.4Hz,1H),3.38(dd,J=7.4,5.3Hz,1H),2.91(d,J=8.0Hz,1H),2.63(dd,J=16.2,2.7Hz,1H),2.48–2.38(m,4H),2.34(s,1H),2.10(dd,J=14.8,4.4Hz,1H),1.97–1.77(m,4H),1.70–1.61(m,2H),1.53(d,J=10.8Hz,1H),1.38(dd,J=10.7,2.8Hz,1H).13C NMR(100MHz,CDCl3)δ:154.59,150.02,149.40,148.42,147.26,145.45,144.27,143.63,136.99,133.05,129.84,128.97,128.50,123.00,122.77,121.76,120.45,120.31,107.36,77.89,53.75,50.91,49.25,49.20,46.46,38.25,37.22,21.78,20.65,12.62.
化合物C5的制备:
制备方法同化合物C1,将苯乙炔改成4-三氟甲基苯乙炔,得白色固体即化合物C5,39.3mg,收率56%,熔点:114-116℃。
IRνmax(cm-1):3420,2930,2862,1622,1468,1326,1171,1123,1064,850,554.HRMS(ESI)m/z calculated for C34H33O4N3F3S[M+H]+:636.2138,found:636.2138.1H NMR(400MHz,CDCl3)δ:7.89(d,J=8.1Hz,2H),7.75–7.67(m,2H),7.64(d,J=8.2Hz,2H),7.40–7.18(m,3H),6.84(d,J=8.1Hz,1H),6.77(d,J=8.1Hz,1H),5.19(t,J=2.5Hz,1H),5.10(s,1H),4.68(dd,J=14.2,5.7Hz,1H),4.57(dd,J=14.2,5.8Hz,1H),3.37(t,J=5.8Hz,1H),2.83–2.74(m,1H),2.73–2.63(m,2H),2.45(s,3H),2.15–2.02(m,1H),1.94(s,3H),1.87(q,J=7.1,5.7Hz,1H),1.66(dd,J=10.6,4.6Hz,2H),1.58(d,J=10.9Hz,1H),1.45(dd,J=10.8,2.6Hz,1H).13C NMR(100MHz,CDCl3)δ:154.46,147.20,146.42,145.55,144.74,143.61,133.80,133.20,130.10,129.85,129.78,129.45,129.35,128.20,125.87,125.83,125.80,125.76,125.72,125.44,122.73,121.55,120.60,107.47,78.07,53.69,51.01,49.66,49.31,46.59,38.25,37.45,21.70,20.73,12.88.
化合物C6的制备:
制备方法同化合物C1,将苯乙炔改成4-甲基苯乙炔,得白色固体即化合物C6,37.8mg,收率59%,熔点:194-196℃。
IRνmax(cm-1):3423,2920,1654,1378,1325,1171,1126,891,839,813,769,551.HRMS(ESI)m/z calculated for C34H36O4N3S[M+H]+:582.2421,found:582.2418.1H NMR(400MHz,CDCl3)δ:7.85–7.74(m,2H),7.73–7.64(m,2H),7.42–7.29(m,2H),7.26(t,J=4.0Hz,3H),6.90(d,J=8.2Hz,1H),6.85(d,J=8.1Hz,1H),5.23(t,J=2.4Hz,1H),5.12(d,J=2.2Hz,1H),4.67(dd,J=14.2,6.1Hz,1H),4.55(dd,J=14.2,5.8Hz,1H),3.40(t,J=5.9Hz,1H),2.87–2.72(m,2H),2.67(dt,J=16.2,2.9Hz,1H),2.50(s,3H),2.42(s,3H),2.12(dt,J=15.0,4.4Hz,1H),2.00(d,J=13.5Hz,1H),1.95(s,3H),1.96–1.80(m,1H),1.78–1.66(m,2H),1.61(d,J=10.9Hz,1H),1.47(dd,J=10.7,2.7Hz,1H).
13C NMR(100MHz,CDCl3)δ:154.67,147.91,147.29,145.50,144.72,143.88,138.10,133.29,129.90,129.56,129.26,128.37,127.64,125.71,121.56,120.56,120.30,107.43,78.11,53.78,51.06,49.50,49.37,46.60,38.31,37.45,21.81,21.36,20.78,12.82.
化合物C7的制备:
制备方法同化合物C1,将苯乙炔改成4-氯苯乙炔,得白色固体即化合物C7,36.4mg,收率55%,熔点:112-115℃。
IRνmax(cm-1):3416,2927,2862,1597,1467,1369,1195,1171,1093,1045,836,554.HRMS(ESI)m/z calculated for C33H33O4N3ClS[M+H]+:602.1875,found:602.1877.1HNMR(400MHz,CDCl3)δ:7.82–7.60(m,4H),7.39–7.32(m,2H),7.29(d,J=8.1Hz,2H),7.23(s,1H),6.85(d,J=8.1Hz,1H),6.77(d,J=8.1Hz,1H),5.18(t,J=2.5Hz,1H),5.07(d,J=2.2Hz,1H),4.64(dd,J=14.1,5.9Hz,1H),4.51(dd,J=14.2,5.9Hz,1H),3.35(t,J=5.9Hz,1H),2.79–2.69(m,2H),2.68–2.59(m,1H),2.45(s,3H),2.11–2.02(m,1H),1.98–1.82(m,5H),1.72–1.61(m,2H),1.56(d,J=10.9Hz,1H),1.43(dd,J=10.9,2.6Hz,1H).
13C NMR(100MHz,CDCl3)δ:154.57,147.26,146.82,145.60,144.75,143.79,133.95,133.28,129.94,129.37,129.06,128.97,128.30,127.08,121.58,120.88,120.62,107.50,78.12,53.79,51.06,49.63,49.34,46.64,38.33,37.50,21.82,20.80,12.89.
化合物C8的制备:
制备方法同化合物C1,将苯乙炔改成4-氟苯乙炔,得白色固体即化合物C8,36.7mg,收率57%,熔点:109-112℃。
IRνmax(cm-1):3424,2929,2862,1597,1561,1497,1467,1368,1224,1171,1094,1045,841,554.HRMS(ESI)m/z calculated for C33H33O4N3FS[M+H]+:586.2170,found:586.2168.1H NMR(400MHz,CDCl3)δ:7.82–7.60(m,4H),7.28(d,J=8.2Hz,2H),7.19(s,1H),7.12–6.97(m,2H),6.84(d,J=8.1Hz,1H),6.76(d,J=8.1Hz,1H),5.17(t,J=2.4Hz,1H),5.07(d,J=2.1Hz,1H),4.63(dd,J=14.2,5.9Hz,1H),4.50(dd,J=14.1,5.9Hz,1H),3.34(t,J=5.9Hz,1H),2.80–2.68(m,2H),2.68–2.56(m,1H),2.44(s,3H),2.06(dt,J=14.7,4.3Hz,1H),2.02–1.73(m,5H),1.65(dd,J=10.6,4.5Hz,2H),1.56(d,J=10.8Hz,1H),1.42(dd,J=10.7,2.7Hz,1H).13C NMR(100MHz,CDCl3)δ:163.87,161.42,154.52,147.18,146.93,145.51,144.67,143.74,133.20,129.85,129.30,128.23,127.52,127.44,126.61,121.48,120.53,120.45,115.86,115.64,107.42,78.05,53.71,50.99,49.52,49.29,46.56,38.25,37.42,21.73,20.71,12.81.
C9-C16的制备反应式如下:
上述制备方法步骤如下:
化合物12的合成:
将赤霉酸(GA3)(5.19g,15mmol)和1.2M的盐酸(30mL)混合,在氮气保护下,65℃反应3h,反应结束后,,加入20mL冰水冷却,抽滤,水洗,干燥得到白色固体,即化合物12,2.81g,收率66%,未经进一步处理直接做下一步反应。
化合物13的合成:
将化合物12(2.81g,9.89mmol)溶于丙酮(75mL)中,在冰水浴下加入硫酸二甲酯(1.18g,9.40mmol)和碳酸钾(2.73g,19.78mmol),加完后撤去冰水浴,室温反应10h,反应完毕后,减压蒸出反应液,加入40mL水,水相用乙酸乙酯(3×80mL)萃取,合并有机相,依次用水(30mL)、饱和食盐水(2×40mL)洗,用无水硫酸钠干燥有机相,减压蒸干,粗产品经柱层析(石油醚/乙酸乙酯=2:1)得白色固体即化合物13,2.42g,收率82%。
1H NMR(400MHz,CDCl3)δ:7.14(t,J=7.5Hz,1H),7.02(d,J=7.6Hz,1H),6.94(d,J=7.3Hz,1H),5.01(d,J=2.6Hz,1H),4.78(d,J=2.2Hz,1H),3.98(s,1H),3.78(s,3H),2.82(dd,J=12.5,5.0Hz,1H),2.31–2.10(m,7H),2.05–1.87(m,3H),1.73(ddd,J=11.9,4.8,2.3Hz,1H),1.60(qd,J=12.8,5.2Hz,1H).13C NMR(100MHz,CDCl3)δ:171.94,154.42,144.47,138.36,135.06,129.04,127.52,119.79,103.37,80.61,77.47,77.16,76.84,54.83,53.47,52.14,51.89,48.83,39.46,34.28,22.08,19.80.
化合物14的合成:
在氮气保护下,将化合物13(2.41g,8.12mmol)溶于无水的四氢呋喃(65mL)中,在冰水浴的条件下,分批加入四氢铝锂(617mg,16.24mmol),加完后移除冰水浴,在室温反应3.5h,反应结束,缓慢加入30mL冰水,水相用乙酸乙酯(3×90mL)萃取,合并有机相,依次用水(2×30mL)、饱和食盐水(2×30mL)洗,用无水硫酸钠干燥有机相,减压蒸干,得粗产物1.78g,粗产物未经柱层析直接做下一步反应。
化合物15的合成:
将化合物14(1.78g,6.59mmol)溶于无水的二氯甲烷(50mL)中,分别加入二异丙基乙胺(1.28g,12.75mmol)、对甲苯磺酰氯(1.50g,7.91mmol)、4-二甲氨基吡啶(160.8mg,1.32),在室温反应7.5h,反应结束,减压蒸干,粗产物经柱层析(石油醚/乙酸乙酯=3:1)得白色粉末即化合物15,2.31g。两步的总收率为67%。
1H NMR(400MHz,CDCl3)δ:7.91–7.77(m,2H),7.35(d,J=8.1Hz,2H),7.04(t,J=7.4Hz,1H),6.87(dd,J=7.5,4.5Hz,2H),5.04(d,J=2.5Hz,1H),4.81(dd,J=10.1,5.3Hz,1H),4.69(d,J=1.9Hz,1H),4.22(dd,J=10.1,8.7Hz,1H),3.36(dd,J=8.6,5.3Hz,1H),2.64(dd,J=12.5,5.0Hz,1H),2.49(d,J=27.9Hz,1H),2.43(s,3H),2.30–2.10(m,5H),2.00–1.85(m,2H),1.84–1.74(m,2H),1.70(ddd,J=12.0,5.2,2.6Hz,1H),1.46(qd,J=12.7,5.3Hz,1H).
13C NMR(100MHz,CDCl3)δ:154.24,145.02,144.96,138.77,133.60,132.43,129.91,129.35,127.90,127.01,120.00,103.51,79.78,68.84,53.08,51.30,49.02,47.68,39.19,31.30,21.80,21.57,20.64.
化合物16的合成:
将化合物15(2.31g,5.44mmol)和叠氮化钠(1.06g,16.32mmol)溶于无水的N,N-二甲基甲酰胺(40mL)。在氮气保护下,80℃反应3.8h,反应结束后,加入25mL水,水相用乙酸乙酯(3×75mL)萃取,合并有机相,依次用水(3×20mL)、饱和食盐水(4×20mL)洗,有机相用无水硫酸钠干燥,减压蒸干,粗产品经柱层析(石油醚/乙酸乙酯=4:1)得白色固体即化合物16,1.24g。产率为77%。
1H NMR(400MHz,CDCl3)δ:7.11(t,J=7.4Hz,1H),6.95(t,J=8.4Hz,2H),5.06(d,J=2.5Hz,1H),4.83(s,1H),4.22(dd,J=12.7,5.3Hz,1H),3.63(dd,J=12.6,8.8Hz,1H),3.31(dd,J=8.8,5.5Hz,1H),2.72(dd,J=12.6,5.0Hz,1H),2.41–2.30(m,5H),2.29–2.20(m,2H),2.05(s,1H),2.02–1.85(m,3H),1.80–1.71(m,1H),1.55(qd,J=12.8,5.2Hz,1H).13C NMR(100MHz,CDCl3)δ:154.76,145.16,140.19,133.90,129.61,127.02,120.12,103.66,80.18,53.47,51.51,50.73,49.13,47.94,39.44,31.58,22.07,20.95.
化合物C9的制备:
将化合物16(50mg,0.10mmol)、苯乙炔(20.4mg,0.22mmol)、醋酸铜(30.0mg,0.15mmol)、抗坏血酸钠(39.6mg,0.20mmol)、水(2mL)和四氢呋喃(8mL)混合,反应6h,反应结束,加入9mL水,水相用乙酸乙酯(3×18mL)萃取,合并有机相,依次用水(2×7mL)、饱和食盐水(2×7mL)洗,用无水硫酸钠干燥有机相,减压蒸干,粗产品经柱层析(石油醚/乙酸乙酯=2:1)得白色固体即化合物C9,25.0mg,收率63%,熔点:203-205℃。
IRνmax(cm-1):3507,2924,2865,1658,1463,1327,1219,1156,1083,899,762,693.HRMS(ESI)m/z calculated for C26H28ON3[M+H]+:398.2227,found:398.2226.1H NMR(400MHz,CDCl3)δ:7.90(s,1H),7.83(d,J=7.7Hz,2H),7.42(t,J=7.5Hz,2H),7.33(t,J=7.4Hz,1H),7.14(t,J=7.5Hz,1H),6.98(t,J=7.6Hz,2H),5.32(dd,J=14.1,5.2Hz,1H),4.99(s,1H),4.86–4.67(m,2H),3.91(dd,J=11.1,5.0Hz,1H),2.68(dt,J=12.9,6.4Hz,2H),2.39(s,3H),2.20(dt,J=12.0,5.3Hz,1H),1.96(d,J=17.2Hz,1H),1.92–1.75(m,2H),1.66(dd,J=12.4,4.9Hz,1H),1.53(dq,J=9.0,5.6Hz,2H),0.76(d,J=10.2Hz,1H).
13C NMR(100MHz,CDCl3)δ:154.00,148.26,145.31,139.40,133.52,130.49,130.03,128.98,128.41,127.40,125.88,120.58,119.72,104.20,79.87,53.53,51.67,49.50,49.40,48.19,38.92,31.08,22.07,21.50.
化合物C10的制备:
制备方法同化合物C9,将苯乙炔改成4-溴苯乙炔,得白色固体即化合物C10,28.6mg,收率60%,熔点:233-236℃。
IRνmax(cm-1):3509,2932,2850,1657,1452,1328,1083,971,897,793,508.
HRMS(ESI)m/z calculated for C26H27ON3Br[M+H]+:476.1332,found:[M+H]+476.1329,[M+2+H]+478.1298.1H NMR(400MHz,CDCl3)δ:7.89(s,1H),7.71(d,J=8.2Hz,2H),7.55(d,J=8.5Hz,2H),7.14(t,J=7.5Hz,1H),6.98(t,J=6.9Hz,2H),5.41–5.24(m,1H),4.99(d,J=2.7Hz,1H),4.85–4.68(m,2H),3.91(dd,J=11.1,5.0Hz,1H),2.78–2.62(m,2H),2.39(s,3H),2.21(dt,J=12.0,5.2Hz,1H),2.01–1.93(m,1H),1.85(dt,J=12.2,6.2Hz,1H),1.66(d,J=12.6Hz,2H),1.54(tq,J=12.4,7.1,6.4Hz,2H),0.73(dd,J=10.3,2.4Hz,1H).13C NMR(100MHz,CDCl3)δ:153.97,147.30,145.27,139.29,133.52,132.17,130.10,129.46,127.51,127.41,127.37,122.36,120.65,119.77,104.27,79.91,53.55,51.72,49.61,49.44,48.28,38.97,31.11,22.10,21.53.
化合物C11的制备:
制备方法同化合物C9,将苯乙炔改成4-甲氧基苯乙炔,得白色固体即化合物C11,29.1mg,收率68%,熔点:199-200℃。
IRνmax(cm-1):3406,2927,2859,1723,1657,1462,1332,1223,1055,894,764,694.513.HRMS(ESI)m/z calculated for C27H30O2N3[M+H]+:428.2333,found:428.2337.1HNMR(400MHz,CDCl3)δ:7.81(s,1H),7.75(d,J=8.3Hz,2H),7.13(t,J=7.6Hz,1H),7.04–6.79(m,4H),5.40–5.24(m,1H),4.99(s,1H),4.79(s,1H),4.77–4.61(m,1H),3.97–3.73(m,4H),2.67(d,J=15.4Hz,2H),2.39(s,3H),2.19(dt,J=12.0,5.3Hz,1H),1.99–1.79(m,3H),1.73–1.61(m,1H),1.53(d,J=11.2Hz,2H),0.75(d,J=10.3Hz,1H).13C NMR(100MHz,CDCl3)δ:159.80,154.05,148.12,145.32,139.44,133.52,130.00,127.36,127.17,123.21,120.55,118.94,114.38,104.15,79.85,55.45,53.51,51.65,49.44,49.38,48.14,38.92,31.05,22.07,21.48.
化合物C12的制备:
制备方法同化合物C9,将苯乙炔改成2-乙炔基吡啶,经柱层析(石油醚/乙酸乙酯=1:2)得白色固体即化合物C12,23.5mg,收率59%,熔点:107-110℃。
IRνmax(cm-1):3415,2930,2865,1734,1603,1461,1421,1248,1202,1088,1046,783,742,542.HRMS(ESI)m/z calculated for C25H27ON4[M+H]+:399.2179,found:399.2177.1H NMR(400MHz,CDCl3)δ:8.44(s,1H),8.43–8.37(m,1H),7.88(d,J=7.9Hz,1H),7.75(td,J=7.7,1.8Hz,1H),7.27(ddd,J=7.6,4.7,1.3Hz,1H),7.15(t,J=7.5Hz,1H),6.99(dd,J=7.4,5.2Hz,2H),5.40–5.26(m,1H),5.12(d,J=2.6Hz,1H),4.90(s,1H),4.78(dd,J=14.0,12.1Hz,1H),3.89(dd,J=12.2,4.8Hz,1H),2.88–2.64(m,2H),2.41(s,3H),2.29–2.16(m,1H),2.13–1.98(m,2H),1.89(td,J=12.3,5.1Hz,1H),1.77–1.67(m,1H),1.67–1.51(m,2H),0.86(dd,J=10.2,2.2Hz,1H).13C NMR(100MHz,CDCl3)δ:154.73,149.30,148.90,147.93,145.21,139.21,137.09,133.55,130.01,127.36,123.14,122.04,120.58,120.43,103.97,79.53,53.29,52.04,49.54,49.07,48.54,39.25,30.99,21.94,21.56.
化合物C13的制备:
制备方法同化合物C9,将苯乙炔改成4-三氟甲基苯乙炔,得白色固体即化合物C13,28.4mg,收率62%,熔点:224-226℃。
IRνmax(cm-1):3512,2939,1620,1456,1326,1165,1127,1062,797.HRMS(ESI)m/zcalculated for C27H27ON3F3[M+H]+:466.2101,found:466.2095.1H NMR(400MHz,DMSO-d6)δ:8.97(s,1H),8.09(d,J=8.1Hz,2H),7.85(d,J=8.1Hz,2H),7.10(t,J=7.4Hz,1H),6.96(t,J=8.1Hz,2H),5.38(dd,J=14.2,5.1Hz,1H),4.91–4.62(m,4H),4.03–3.85(m,1H),2.74–2.55(m,2H),2.36(s,3H),2.23–2.06(m,1H),1.71(t,J=15.5Hz,2H),1.54–1.41(m,1H),1.39–1.15(m,2H),0.61(d,J=10.1Hz,1H).13C NMR(100MHz,DMSO-d6)δ:154.73,145.18,145.08,139.76,134.82,133.50,129.63,126.89,126.06,125.70,122.87,120.04,103.05,78.37,53.20,51.00,48.77,48.55,46.97,30.82,21.84,20.86.
化合物C14的制备:
制备方法同化合物C9,将苯乙炔改成4-甲基苯乙炔,得白色固体即化合物C14,26.8mg,收率65%,熔点:200-204℃。
IRνmax(cm-1):3494,2928,2863,1739,1660,1500,1460,1326,1236,1090,1073,977,885,814,738,511.HRMS(ESI)m/z calculated for C27H30ON3[M+H]+:412.2383,found:412.2388.1H NMR(400MHz,CDCl3)δ:7.86(s,1H),7.72(d,J=7.8Hz,2H),7.21(d,J=7.8Hz,2H),7.13(t,J=7.5Hz,1H),6.97(t,J=8.2Hz,2H),5.30(dd,J=14.1,5.2Hz,1H),4.99(d,J=2.6Hz,1H),4.79(d,J=2.1Hz,1H),4.72(dd,J=14.1,11.0Hz,1H),3.88(dd,J=11.1,5.1Hz,1H),2.78–2.57(m,2H),2.37(d,J=8.8Hz,6H),2.18(dtd,J=10.5,5.4,2.8Hz,1H),2.05–1.90(m,2H),1.84(td,J=12.2,5.1Hz,1H),1.71–1.59(m,1H),1.59–1.39(m,2H),0.75(dd,J=10.2,2.3Hz,1H).13C NMR(100MHz,CDCl3)δ:154.02,148.29,145.31,139.43,138.26,133.50,129.98,129.62,127.66,127.34,125.77,120.53,119.42,104.15,79.83,53.50,51.62,49.43,49.36,48.11,38.90,31.04,22.05,21.47,21.38.
化合物C15的制备:
制备方法同化合物C9,将苯乙炔改成4-氯苯乙炔,得白色固体即化合物C15,25.1mg,收率58%,熔点:235-237℃。
IRνmax(cm-1):3507,2936,2856,1657,1456,1326,1218,1156,1084,970,898,792,510.HRMS(ESI)m/z calculated for C26H27ON3Cl[M+H]+:432.1837,found:432.1834.1HNMR(400MHz,CDCl3)δ:7.88(s,1H),7.82–7.67(m,2H),7.45–7.34(m,2H),7.14(t,J=7.5Hz,1H),6.98(t,J=6.9Hz,2H),5.39–5.30(m,1H),4.99(t,J=2.6Hz,1H),4.84–4.68(m,2H),3.91(dd,J=11.1,5.1Hz,1H),2.76–2.61(m,2H),2.39(s,3H),2.28–2.14(m,1H),1.97(dq,J=17.2,2.3Hz,1H),1.86(td,J=12.2,5.1Hz,1H),1.67(d,J=12.7Hz,2H),1.61–1.44(m,2H),0.74(dd,J=10.2,2.3Hz,1H).13C NMR(100MHz,CDCl3)δ:153.97,147.29,145.28,139.30,134.23,133.52,130.10,129.22,129.01,127.50,127.13,127.09,120.65,119.74,104.26,79.91,53.56,51.72,49.60,49.44,48.28,38.97,31.11,22.10,21.53.
化合物C16的制备:
制备方法同化合物C9,将苯乙炔改成4-氟苯乙炔,得白色固体即化合物C16,24.9mg,收率60%,熔点:211-213℃。
IRνmax(cm-1):3506,2934,2855,1658,1558,1498,1459,1326,1223,1157,1083,899,843,791,521.HRMS(ESI)m/z calculated for C26H27ON3F[M+H]+:416.2133,found:416.2137.1H NMR(400MHz,DMSO-d6)δ:8.77(s,1H),7.98–7.76(m,2H),7.40–7.24(m,2H),7.09(t,J=7.4Hz,1H),6.95(t,J=8.4Hz,2H),5.34(dd,J=14.1,5.2Hz,1H),4.84(d,J=10.4Hz,2H),4.79–4.66(m,2H),3.93(dd,J=11.2,5.0Hz,1H),2.75–2.56(m,2H),2.36(s,3H),2.13(dt,J=11.6,5.1Hz,1H),1.70(td,J=14.2,12.6,3.8Hz,2H),1.55–1.42(m,1H),1.41–1.25(m,2H),0.72–0.52(m,1H).13C NMR(101MHz,DMSO)δ163.06,160.63,154.75,145.72,145.11,139.81,133.50,129.63,127.47,127.44,127.25,127.17,126.87,121.47,120.03,116.05,115.84,103.03,78.39,53.21,51.00,48.67,48.57,46.96,40.05,30.81,21.86,20.88.
C17-C24的制备反应式如下:
上述制备方法步骤如下:
化合物17的合成:
将化合物8(1.1g,3.50mmol)溶于二氯甲烷(30mL)中,依次加入咪唑(357.3mg,5.25mmol)和叔丁基二甲基氯硅烷(739.9mg,4.90mmol),室温反应4h,反应结束,加入20mL水,水相用二氯甲烷(3×40mL)萃取,合并有机相,依次用水(20mL)、饱和食盐水(2×15mL)洗,有机相用无水硫酸钠干燥,减压蒸干,粗产物经柱层析(石油醚/乙酸乙酯=6:1)得1.40g产物即化合物17。收率93%。
1H NMR(400MHz,CDCl3)δ:6.82(d,J=8.0Hz,1H),6.67(d,J=8.0Hz,1H),5.16(t,J=2.4Hz,1H),5.02(d,J=2.1Hz,1H),3.63(d,J=10.3Hz,4H),3.36(dd,J=8.5,2.5Hz,1H),2.73(dt,J=16.4,2.9Hz,1H),2.56–2.39(m,1H),2.10(s,5H),1.94(ddt,J=15.0,10.3,7.9Hz,1H),1.83–1.65(m,2H),1.60(dd,J=10.6,2.6Hz,1H),1.54(dd,J=10.7,2.3Hz,1H),1.01(s,9H),0.21(d,J=2.5Hz,6H).13C NMR(100MHz,CDCl3)δ:172.65,155.50,152.41,141.11,138.84,126.08,119.78,117.54,106.65,78.46,56.68,53.92,51.70,48.74,47.60,38.61,38.43,25.85,21.15,18.30,13.09,-4.15,-4.17.
化合物18的合成:
在氮气保护下,将化合物17(1.40g,3.26mmol)溶于无水的四氢呋喃(30mL)中,在冰水浴的条件下,加入四氢铝锂(248.8mg,6.52mmol),加完后移除冰水浴,在室温反应5h,反应完毕后,缓慢加入20mL冰水,水相用乙酸乙酯(3×80mL)萃取,合并有机相,依次用水(20mL)、饱和食盐水(2×15mL)洗,用无水硫酸钠干燥有机相,减压蒸干,得粗产物1.03g,未经柱层析直接做下一步反应。
化合物19的合成:
将化合物18(1.03g,2.57mmol)溶于无水的二氯甲烷(30mL)中,分别加入二异丙基乙胺(464.1mg,3.60mmol)、对甲苯磺酰氯(512.7mg,2.70mmol)、4-二甲氨基吡啶(62.7mg,0.514mmol),在室温反应9h,反应结束,减压蒸干,粗产物经柱层析(石油醚/乙酸乙酯=2:1)得白色粉末即化合物19,1.10g。两步的总收率为61%。
1H NMR(400MHz,CDCl3)δ:7.66(d,J=8.1Hz,2H),7.29(d,J=8.0Hz,2H),6.75(d,J=8.0Hz,1H),6.62(d,J=8.0Hz,1H),5.12(d,J=2.3Hz,1H),5.00(s,1H),4.03(qd,J=10.2,6.3Hz,2H),3.10–2.92(m,2H),2.80(dt,J=16.4,2.9Hz,1H),2.42-2.37(m,4H),2.14–2.01(m,2H),1.98(s,3H),1.87(ddt,J=15.4,11.8,8.3Hz,1H),1.72–1.55(m,2H),1.48–1.34(m,2H),1.00(s,9H),0.19(d,J=4.0Hz,6H).13C NMR(100MHz,CDCl3)δ:155.44,152.54,144.79,141.42,137.80,132.66,129.80,127.83,126.14,119.59,117.23,106.65,78.03,68.19,53.03,49.92,48.82,46.41,38.33,37.88,25.80,21.64,20.76,18.23,12.86,-4.18,-4.24.
化合物20的合成:
将化合物19(1.10g,1.98mmol)溶于无水的四氢呋喃,然后加入四正丁基氟化铵(517.3mg,1.98mmol),室温反应1h,反应结束,加入25mL水,用乙酸乙酯(3×50mL)萃取,合并有机相,依次用水(18mL)、饱和食盐水(2×18mL)洗,有机相用无水硫酸钠干燥,减压蒸干,经柱层析(石油醚/乙酸乙酯=2:1-1:1)得白色粉末即化合物20,750.9mg产物。收率86%。
1H NMR(400MHz,CDCl3)δ:7.66(d,J=8.0Hz,2H),7.29(d,J=8.1Hz,2H),6.74(d,J=7.9Hz,1H),6.61(d,J=7.9Hz,1H),5.14(t,J=2.3Hz,1H),5.03(d,J=2.4Hz,1H),4.03(qd,J=10.3,6.3Hz,2H),3.09–2.94(m,2H),2.81(dt,J=16.5,3.0Hz,1H),2.40-2.45(m,4H),2.16–2.02(m,1H),1.97(s,3H),1.88(tt,J=15.1,8.6Hz,1H),1.67(qd,J=13.1,12.4,8.0Hz,2H),1.51–1.39(m,2H).13C NMR(100MHz,CDCl3)δ:155.32,153.03,145.04,141.49,137.31,132.53,129.93,127.92,121.75,120.02,113.86,106.95,78.46,68.39,53.20,49.86,48.92,46.48,38.36,37.95,21.75,20.91,12.04.
化合物21的合成:
将化合物20(750.9mg,1.70mmol)和叠氮化钠(331.5mg,5.10mmol)溶于无水的N,N-二甲基甲酰胺(18mL)。在氮气保护下,80℃反应3h,反应结束后,加入20mL水,用乙酸乙酯(3×50mL)萃取,合并有机相,依次用水(3×15mL)、饱和食盐水(4×18mL)洗,有机相用无水硫酸钠干燥,减压蒸干,粗产品经柱层析(石油醚/乙酸乙酯=3:1)得白色固体即化合物21,423.0mg,产率为80%。
1H NMR(400MHz,CDCl3)δ:6.79(d,J=7.9Hz,1H),6.64(d,J=7.9Hz,1H),5.87(s,1H),5.18(t,J=2.1Hz,1H),5.09(s,1H),3.41(d,J=6.4Hz,2H),3.10(d,J=8.1Hz,1H),2.92(t,J=6.4Hz,1H),2.83(dt,J=16.2,3.0Hz,1H),2.51(d,J=16.2Hz,1H),2.20(s,3H),2.17–2.08(m,2H),1.93(ddt,J=15.3,11.4,8.2Hz,1H),1.80–1.62(m,2H),1.50(t,J=2.7Hz,2H).13C NMR(100MHz,CDCl3)δ:155.29,153.00,143.58,137.12,121.63,119.95,113.70,107.04,78.73,53.52,50.87,50.09,49.03,46.49,38.40,38.02,20.95,12.29.
化合物C17的制备:
将化合物21(44mg,0.14mmol)、苯乙炔(28.6mg,0.28mmol)、醋酸铜(42.0mg,0.21mmol)、抗坏血酸钠(55.4mg,0.28mmol)、水(2mL)和四氢呋喃(8mL)混合,反应8h,反应结束,加入9mL水,水相用乙酸乙酯(3×18mL)萃取,合并有机相,依次用水(2×6mL)、饱和食盐水(2×6mL)洗,用无水硫酸钠干燥有机相,减压蒸干,粗产品经柱层析(石油醚/乙酸乙酯=2:1)得白色固体即化合物C17,34.3mg,收率59%,熔点:141-142℃。
IRνmax(cm-1):3385,2929,2861,1639,1600,1465,1446,1356,1333,1262,1159,1054,895,822,764,695.HRMS(ESI)m/z calculated for C26H28O2N3[M+H]+:414.2176,found:414.2177.1H NMR(400MHz,CDCl3)δ:7.78–7.56(m,2H),7.33(dd,J=8.3,6.6Hz,2H),7.28(s,1H),7.23(s,1H),6.72(q,J=8.1Hz,3H),5.11(s,1H),4.98(s,1H),4.57(dd,J=14.0,6.3Hz,1H),4.34(dd,J=14.0,6.9Hz,1H),3.31(t,J=6.7Hz,1H),2.80(d,J=7.8Hz,1H),2.61–2.41(m,2H),2.29(s,1H),2.13–1.97(m,1H),1.92–1.68(m,1H),1.78(s,3H),1.62(dd,J=10.9,7.0Hz,2H),1.49(d,J=10.9Hz,1H),1.45–1.34(m,1H).
13C NMR(100MHz,CDCl3)δ:154.85,153.48,147.83,143.22,136.85,130.31,128.98,128.37,125.88,122.12,120.78,120.30,114.11,107.33,78.37,53.94,50.99,50.02,49.18,46.31,38.38,37.49,20.95,11.79.
化合物C18的制备:
制备方法同化合物C17,将苯乙炔改成4-溴苯乙炔,得白色固体即化合物C1839.3mg,收率57%,熔点:151-153℃。
IRνmax(cm-1):3424,2927,2859,1638,1601,1451,1264,1120,1069,1011,823,514.HRMS(ESI)m/z calculated for C26H27O2N3Br[M+H]+:492.1281,found:[M+H]+492.1280,[M+2+H]+494.1256.1H NMR(400MHz,CDCl3)δ:
7.58(d,J=8.5Hz,2H),7.52–7.44(m,2H),7.28(s,1H),6.80(d,J=8.0Hz,1H),6.72(d,J=7.9Hz,1H),6.31(s,1H),5.16(d,J=2.5Hz,1H),5.04(s,1H),4.63(dd,J=13.9,6.2Hz,1H),4.39(dd,J=14.0,7.0Hz,1H),3.35(t,J=6.7Hz,1H),2.83(d,J=8.0Hz,1H),2.67–2.47(m,2H),2.10(q,J=6.5,5.9Hz,2H),1.90(d,J=8.9Hz,2H),1.80(s,3H),1.66(t,J=17.1Hz,1H),1.53(d,J=10.9Hz,1H),1.46(dd,J=10.7,2.2Hz,1H).13C NMR(100MHz,CDCl3)δ:154.83,153.36,146.85,143.22,137.03,132.13,129.34,127.38,122.26,122.03,120.82,120.40,114.10,107.40,78.37,53.99,51.01,50.10,49.25,46.36,38.41,37.54,20.99,11.75.
化合物C19的制备:
制备方法同化合物C17,将苯乙炔改成4-甲氧基苯乙炔,得白色固体即化合物C19,37.9mg,收率61%,熔点:150-154℃。
IRνmax(cm-1):3415,2929,1658,1618,1500,1460,1249,1176,1054,1031,835,605,533.HRMS(ESI)m/z calculated for C27H30O3N3[M+H]+:444.2282,found:444.2285.1H NMR(400MHz,CDCl3)δ:7.61(d,J=8.3Hz,2H),7.40(s,1H),7.24(s,1H),6.87(d,J=8.4Hz,2H),6.73(s,2H),5.12(s,1H),4.98(s,1H),4.55(dd,J=14.1,6.2Hz,1H),4.32(dd,J=14.1,6.8Hz,1H),3.77(s,3H),3.38–3.24(m,1H),2.81(d,J=7.5Hz,1H),2.50(q,J=16.5Hz,3H),2.14–1.99(m,1H),1.85(s,1H),1.79(s,3H),1.61(d,J=8.4Hz,2H),1.50(d,J=10.8Hz,1H),1.42(d,J=10.7Hz,1H).13C NMR(100MHz,CDCl3)δ:159.68,154.87,153.63,147.60,143.21,136.62,127.17,122.99,122.20,120.17,120.09,114.38,114.04,107.24,78.30,55.41,53.88,50.95,49.95,49.07,46.25,38.38,37.45,20.90,11.80.
化合物C20的制备:
制备方法同化合物C17,将苯乙炔改成2-乙炔基吡啶,粗产品经柱层析(石油醚/乙酸乙酯=1:2)得白色固体化合物C20,28.5mg,收率49%,熔点:144-147℃。
IRνmax(cm-1):3405,2927,2856,1734,1686,1601,1496,1422,1251,1121,1053,894,823,784.HRMS(ESI)m/z calculated for C25H27O2N4[M+H]+:415.2129,found:415.2128.1H NMR(400MHz,CDCl3)δ:8.50(d,J=5.0Hz,1H),8.19(d,J=7.9Hz,1H),8.00(s,1H),7.78(td,J=7.7,1.8Hz,1H),7.22(dd,J=7.5,5.0Hz,1H),6.74(d,J=7.9Hz,1H),6.66(d,J=7.9Hz,1H),5.12(t,J=2.4Hz,1H),4.98(s,1H),4.61(dd,J=14.1,7.2Hz,1H),4.36(dd,J=14.1,6.0Hz,1H),3.34(t,J=6.7Hz,1H),3.03–2.83(m,2H),2.56(d,J=16.3Hz,1H),2.39(dt,J=16.2,3.0Hz,1H),2.08(dd,J=13.4,4.9Hz,1H),1.95–1.73(m,4H),1.63(dd,J=11.0,6.5Hz,2H),1.55–1.36(m,2H).13C NMR(101MHz,CDCl3)δ154.96,153.81,149.91,149.10,147.86,143.02,137.53,136.44,123.20,123.15,122.28,120.73,120.14,114.14,107.22,78.20,53.87,51.09,49.91,49.26,46.26,38.44,37.44,20.89,11.95.
化合物C21的制备:
制备方法同化合物C17,将苯乙炔改成4-三氟甲基苯乙炔,得白色固体化合物C21,35.1mg,收率52%,熔点:148-150℃。
IRνmax(cm-1):3387,2929,2862,1623,1451,1326,1167,1123,1065,849,822,598.HRMS(ESI)m/z calculated for C27H27O2N3F3[M+H]+:482.2050,found:482.2047.1HNMR(400MHz,CDCl3)δ:7.80(d,J=8.1Hz,2H),7.60(d,J=8.1Hz,2H),7.36(s,1H),6.78(d,J=8.0Hz,1H),6.75–6.57(m,2H),5.15(t,J=2.4Hz,1H),5.02(s,1H),4.63(dd,J=14.0,6.1Hz,1H),4.40(dd,J=14.0,7.0Hz,1H),3.35(t,J=6.6Hz,1H),2.81(d,J=7.8Hz,1H),2.66–2.46(m,2H),2.36(s,1H),2.21–1.99(m,1H),1.95–1.82(m,1H),1.78(s,3H),1.65(dd,J=10.7,6.3Hz,2H),1.53(d,J=10.9Hz,1H),1.48–1.38(m,1H).13C NMR(100MHz,CDCl3)δ:154.69,153.44,146.48,143.13,136.93,133.73,130.65,130.33,130.00,129.68,125.98,125.94,125.49,122.79,122.10,121.57,120.37,114.11,107.44,78.40,53.97,50.97,50.17,49.16,46.33,38.38,37.51,20.95,11.75.
化合物C22的制备:
制备方法同化合物C17,将苯乙炔改成4-甲基苯乙炔,得白色固体化合物C22,31.1mg,收率52%,熔点:143-147℃。
IRνmax(cm-1):3406,2927,2861,1685,1600,1499,1450,1359,1263,1120,1054,895,822,517.HRMS(ESI)m/z calculated for C27H30O2N3[M+H]+:428.2333,found:428.2329.1H NMR(400MHz,CDCl3)δ:7.59(d,J=7.8Hz,2H),7.28(s,1H),7.16(d,J=7.8Hz,2H),7.12–6.86(m,1H),6.81–6.61(m,2H),5.13(s,1H),4.99(s,1H),4.56(dd,J=14.1,6.3Hz,1H),4.33(dd,J=14.0,6.8Hz,1H),3.31(t,J=6.6Hz,1H),2.81(d,J=7.7Hz,1H),2.64–2.13(m,3H),2.33(s,3H),2.14–1.97(m,1H),1.97–1.72(m,4H),1.74–1.55(m,2H),1.50(d,J=11.0Hz,1H),1.43(d,J=10.8Hz,1H).13C NMR(100MHz,CDCl3)δ154.86,153.55,147.87,143.20,138.22,136.73,129.64,127.45,125.78,122.15,120.47,120.23,114.10,107.28,78.36,53.91,50.98,49.98,49.13,46.28,38.37,37.46,21.36,20.93,11.79.
化合物C23的制备:
制备方法同化合物C17,将苯乙炔改成4-氯苯乙炔,得白色固体即化合物C23,33.3mg,收率53%,熔点:139-142℃。
IRνmax(cm-1):3387,2928,2860,1660,1600,1485,1452,1358,1333,1264,1253,1093,1054,974,895,822,517.HRMS(ESI)m/z calculated for C26H27O2N3Cl[M+H]+:448.1786,found:448.1786.1H NMR(400MHz,CDCl3)δ:7.62(d,J=8.1Hz,2H),7.38–7.28(m,3H),6.90(s,1H),6.83–6.60(m,2H),5.15(s,1H),5.02(s,1H),4.61(dd,J=14.0,6.2Hz,1H),4.38(dd,J=14.0,7.0Hz,1H),3.33(t,J=6.6Hz,1H),2.82(d,J=7.9Hz,1H),2.63–2.46(m,2H),2.44–2.22(m,1H),2.08(dd,J=13.8,5.2Hz,1H),1.87(dd,J=17.5,7.9Hz,1H),1.79(s,3H),1.65(dd,J=10.7,6.6Hz,2H),1.52(d,J=10.9Hz,1H),1.45(d,J=10.9Hz,1H).13C NMR(100MHz,CDCl3)δ:154.79,153.52,146.78,143.15,136.81,134.07,129.15,128.84,127.10,122.11,120.87,120.31,114.08,107.36,78.35,53.94,50.98,50.08,49.15,46.32,38.40,37.51,20.95,11.77.
化合物C24的制备:
制备方法同化合物C17,将苯乙炔改成4-氟苯乙炔,得白色固体即化合物C24,29.0mg,收率48%。熔点:125-128℃。
IRνmax(cm-1):3386,2929,2861,1773,1659,1600,1561,1498,1500,1229,1157,1054,841,599,526.HRMS(ESI)m/z calculated for C26H27O2N3F[M+H]+:432.2082,found:432.2085.1H NMR(400MHz,CDCl3)δ:7.66(dd,J=8.6,5.4Hz,2H),7.28(s,1H),7.04(t,J=8.6Hz,2H),6.86(s,1H),6.78(d,J=8.1Hz,1H),6.73(d,J=8.0Hz,1H),5.14(d,J=2.5Hz,1H),5.02(s,1H),4.61(dd,J=14.1,6.2Hz,1H),4.37(dd,J=15.3,5.7Hz,1H),3.34(t,J=6.7Hz,1H),2.84(d,J=8.0Hz,1H),2.62–2.49(m,2H),2.40(s,1H),2.08(dq,J=12.2,6.7,5.2Hz,1H),1.95–1.82(m,1H),1.79(s,3H),1.65(dd,J=10.7,6.8Hz,2H),1.53(d,J=11.0Hz,1H),1.49–1.40(m,1H).13C NMR(101MHz,CDCl3)δ164.01,161.55,154.78,153.50,146.99,143.19,136.81,127.68,127.60,126.49,122.14,120.62,120.30,116.07,115.85,114.07,107.36,78.37,53.96,50.98,50.07,49.14,46.32,38.40,37.51,20.95,11.76.
C25-C31的制备反应式如下:
上述制备方法步骤如下:
化合物22的合成:
将化合物21(700.0mg,2.25mmol)和二异丙基胺(23mg,0.23mmol)溶于无水的二氯甲烷(15mL),在冰水浴下,缓慢加入N-溴代琥珀酰亚胺(400.5mg,2.25mmol)的二氯甲烷(5mL)溶液,在该温度下反应1h,反应结束后,直接减压蒸干,粗产品经柱层析(石油醚/乙酸乙酯=3:1)得白色固体即化合物22,570.3mg,收率65%。
1H NMR(400MHz,CDCl3)δ:7.05(s,1H),5.55(s,1H),5.18(dd,J=3.2,1.7Hz,1H),5.09(s,1H),3.68–3.30(m,2H),3.13(d,J=8.1Hz,1H),2.91(t,J=6.4Hz,1H),2.82(dt,J=16.2,3.1Hz,1H),2.56–2.46(m,1H),2.27(s,3H),2.09(dd,J=14.9,6.1Hz,1H),1.94(ddt,J=15.4,11.4,8.2Hz,1H),1.86–1.60(m,4H),1.55–1.41(m,2H).13C NMR(100MHz,CDCl3)δ:155.18,149.20,143.37,138.45,123.23,122.76,108.92,107.13,78.30,53.48,50.82,50.02,49.18,46.56,38.38,37.95,20.97,13.32.
化合物C25的制备:
将化合物22(45mg,0.12mmol)、苯乙炔(24.5mg,0.24mmol)、醋酸铜(36.0mg,0.18mmol)、抗坏血酸钠(47.5mg,0.24mmol)、水(2mL)和四氢呋喃(8mL)混合,反应10h,反应毕后,加入10mL水,水相用乙酸乙酯(3×18mL)萃取,合并有机相,依次用水(6mL)、饱和食盐水(2×7mL)洗,用无水硫酸钠干燥有机相,减压蒸干,粗产品经柱层析(石油醚/乙酸乙酯=2:1)得白色固体即化合物C25,36.6mg,收率62%。
IRνmax(cm-1):3504,2938,2846,1658,1617,1558,1498,1454,1327,1241,1178,1083,1036,899,843,792,640,525.HRMS(ESI)m/z calculated for C26H27O2N3Br[M+H]+:492.1281,found:[M+H]+492.1280,[M+2+H]+494.1247.
1H NMR(400MHz,CDCl3)δ:7.88–7.60(m,2H),7.37(td,J=15.9,15.5,7.5Hz,4H),7.07(s,1H),5.68(s,1H),5.16(t,J=2.4Hz,1H),5.04(d,J=2.1Hz,1H),4.62(dd,J=14.0,6.4Hz,1H),4.36(dd,J=14.0,7.2Hz,1H),3.37(t,J=6.8Hz,1H),2.92(d,J=7.9Hz,1H),2.66–2.44(m,2H),2.14–1.98(m,2H),1.98–1.87(m,1H),1.87(s,3H),1.67(dd,J=11.7,6.7Hz,2H),1.55(d,J=10.9Hz,1H),1.44(dd,J=10.9,2.4Hz,1H).13C NMR(100MHz,CDCl3)δ:154.56,149.32,147.96,143.12,138.34,130.44,128.96,128.34,125.85,123.71,123.11,120.46,109.20,107.51,78.09,53.94,50.90,49.66,49.18,46.26,38.24,37.39,20.91,12.68.
化合物C26的制备:
制备方法同化合物C25,将苯乙炔改成4-甲氧基苯乙炔,经柱层析(石油醚/乙酸乙酯=2:1)得白色固体即化合物C26,32.6mg,收率52%。熔点:152-154℃。
IRνmax(cm-1):3423,2928,2859,1774,1617,1561,1499,1459,1335,1250,1177,896,837,532.HRMS(ESI)m/z calculated for C27H29O3N3Br[M+H]+:522.1387,found:[M+H]+522.1386,[M+2+H]+524.1353.1H NMR(400MHz,CDCl3)δ:7.75–7.59(m,2H),7.28(s,1H),7.08(s,1H),6.97–6.87(m,2H),5.64(s,1H),5.16(t,J=2.4Hz,1H),5.05(s,1H),4.61(dd,J=14.0,6.4Hz,1H),4.35(dd,J=14.1,7.3Hz,1H),3.83(s,3H),3.37(t,J=6.8Hz,1H),2.93(d,J=8.0Hz,1H),2.64–2.45(m,2H),2.08(dd,J=15.2,5.6Hz,1H),1.99–1.88(m,2H),1.86(s,3H),1.68(dd,J=11.7,6.7Hz,2H),1.55(d,J=10.9Hz,1H),1.45(dd,J=10.7,2.3Hz,1H).13C NMR(101MHz,CDCl3)δ159.81,154.59,149.31,147.87,143.17,138.35,127.18,123.72,123.11,119.72,114.42,109.18,107.52,78.13,55.47,53.97,50.91,49.65,49.20,46.28,38.25,37.40,20.93,12.67.
化合物C27的制备:
制备方法同化合物C25,将苯乙炔改成2-乙炔基吡啶,经柱层析(石油醚/乙酸乙酯=2:1)得白色固体即化合物C27,24.8mg,收率42%。熔点:149-153℃。
IRνmax(cm-1):3422,2927,2860,1732,1603,1461,1422,1331,1225,1121,1046,894,784.HRMS(ESI)m/z calculated for C25H26O2N4Br[M+H]+:493.1234,found:[M+H]+493.1233,[M+2+H]+495.1199.1H NMR(400MHz,CDCl3)δ:
8.58–8.46(m,1H),8.17(d,J=8.0Hz,1H),7.94(s,1H),7.77(td,J=7.8,1.8Hz,1H),7.22(ddd,J=7.7,4.9,1.2Hz,1H),7.08(s,1H),5.82–5.63(m,1H),5.14(d,J=2.5Hz,1H),5.02(d,J=2.4Hz,1H),4.65(dd,J=14.0,7.2Hz,1H),4.34(dd,J=14.0,6.7Hz,1H),3.40(t,J=7.0Hz,1H),3.05(d,J=8.0Hz,1H),2.65–2.51(m,1H),2.43(dt,J=16.3,3.0Hz,1H),2.11(dd,J=14.7,5.7Hz,1H),2.05–1.79(m,4H),1.75–1.58(m,2H),1.58–1.49(m,1H),1.45(dd,J=10.7,2.7Hz,1H),1.25(s,1H).13C NMR(100MHz,CDCl3)δ:154.64,150.12,149.44,149.40,148.52,142.99,138.13,137.16,123.70,123.11,122.81,120.49,109.35,107.51,78.07,53.99,50.95,49.63,49.26,46.27,38.28,37.35,20.90,12.74。
化合物C28的制备:
制备方法同化合物C25,将苯乙炔改成4-三氟甲基苯乙炔,经柱层析(石油醚/乙酸乙酯=2:1)得白色固体即化合物C28,30.9mg,收率46%。熔点:119-122℃。
IRνmax(cm-1):3405,2929,2861,1622,1461,1325,1190,1123,1064,849,798,597.HRMS(ESI)m/z calculated for C27H26O2N3BrF3[M+H]+:560.1155,found:[M+H]+560.1160,[M+2+H]+562.1141.1H NMR(400MHz,CDCl3)δ:7.86(d,J=8.0Hz,2H),7.66(d,J=8.1Hz,2H),7.41(s,1H),7.09(s,1H),5.61(s,1H),5.18(t,J=2.4Hz,1H),5.07(s,1H),4.67(dd,J=14.0,6.2Hz,1H),4.41(dd,J=14.0,7.2Hz,1H),3.40(t,J=6.7Hz,1H),2.92(d,J=8.0Hz,1H),2.69–2.50(m,2H),2.09(dd,J=14.5,5.2Hz,1H),2.00–1.88(m,1H),1.86(s,3H),1.78(s,1H),1.69(dd,J=11.5,6.7Hz,2H),1.57(d,J=10.9Hz,1H),1.47(dd,J=10.8,2.2Hz,1H).13C NMR(100MHz,CDCl3)δ:154.36,149.24,146.53,142.88,138.24,133.78,130.26,129.93,125.89,125.85,125.40,123.53,123.08,122.70,121.08,109.16,107.51,78.00,53.87,50.80,49.73,49.13,46.20,38.16,37.32,20.84,12.56.
化合物C29的制备:
制备方法同化合物C25,将苯乙炔改成4-甲基苯乙炔,经柱层析(石油醚/乙酸乙酯=2:1)得白色固体即化合物C29,29.1mg,收率48%。熔点:169-171℃。
IRνmax(cm-1):3432,2929,2863,1719,1642,1561,1497,1452,1334,1223,1157,1052,912,865,796,765,527.HRMS(ESI)m/z calculated for C27H29O2N3Br[M+H]+:506.1438,found:[M+H]+506.1436,[M+2+H]+508.1403.
1H NMR(400MHz,CDCl3)δ:7.64(d,J=7.9Hz,2H),7.30(s,1H),7.22(d,J=7.8Hz,2H),7.08(s,1H),5.57(s,1H),5.16(t,J=2.4Hz,1H),5.05(d,J=2.6Hz,1H),4.63(dd,J=14.0,6.4Hz,1H),4.37(dd,J=14.0,7.1Hz,1H),3.38(t,J=6.7Hz,1H),2.92(d,J=8.0Hz,1H),2.69–2.49(m,2H),2.37(s,3H),2.09(dd,J=14.9,5.5Hz,1H),2.00–1.81(m,4H),1.80–1.60(m,3H),1.60–1.51(m,1H),1.46(dd,J=10.8,2.4Hz,1H).13C NMR(100MHz,CDCl3)δ:154.53,149.19,147.97,143.07,138.25,138.11,129.53,127.57,125.65,123.57,122.98,119.93,109.06,107.39,78.02,53.85,50.82,49.52,49.17,46.18,38.14,37.29,21.27,20.84,12.57.
化合物C30的制备:
制备方法同化合物C25,将苯乙炔改成4-氯苯乙炔,经柱层析(石油醚/乙酸乙酯=2:1)得白色固体即化合物C30,27.2mg,收率43%。熔点:166-169℃。
IRνmax(cm-1):3416,2927,2858,1726,1656,1485,1452,1333,1223,1092,1054,975,891,835,517.HRMS(ESI)m/z calculated for C26H26O2N3BrCl[M+H]+:526.0891,found:[M+H]+526.0896,[M+2+H]+528.0861.1H NMR(400MHz,CDCl3)δ:7.68(d,J=8.3Hz,2H),7.38(d,J=8.1Hz,2H),7.27(s,1H),7.09(s,1H),5.59(s,1H),5.17(t,J=2.4Hz,1H),5.06(d,J=2.6Hz,1H),4.65(dd,J=14.0,6.3Hz,1H),4.38(dd,J=14.0,7.1Hz,1H),3.38(t,J=6.7Hz,1H),2.92(d,J=8.0Hz,1H),2.72–2.45(m,2H),2.09(dd,J=14.6,5.2Hz,1H),1.93(dq,J=11.6,8.0,7.4Hz,1H),1.86(s,3H),1.79–1.62(m,3H),1.56(d,J=10.8Hz,1H),1.46(dd,J=10.8,2.3Hz,1H).13C NMR(100MHz,CDCl3)δ:154.42,149.22,146.86,142.95,138.24,134.01,129.07,128.87,126.97,123.53,123.03,120.35,109.12,107.47,78.01,53.86,50.81,49.63,49.15,46.19,38.15,37.31,20.84,12.56.
化合物C31的制备:
制备方法同化合物C25,将苯乙炔改成4-氟苯乙炔,经柱层析(石油醚/乙酸乙酯=2:1)得白色固体即化合物C31,27.5mg,收率45%。熔点:151-154℃。
IRνmax(cm-1):3415,2927,2861,1726,1655,1499,1459,1334,1222,1120,1054,889,820,793,517.HRMS(ESI)m/z calculated for C26H26O2N3BrF[M+H]+:510.1187,found:[M+H]+510.1189,[M+2+H]+512.1156.1H NMR(400MHz,CDCl3)δ:7.87–7.56(m,2H),7.31(s,1H),7.16–7.00(m,3H),5.64(s,1H),5.17(d,J=2.5Hz,1H),5.05(d,J=2.2Hz,1H),4.64(dd,J=14.0,6.4Hz,1H),4.37(dd,J=14.0,7.2Hz,1H),3.38(t,J=6.8Hz,1H),2.93(d,J=8.0Hz,1H),2.70–2.47(m,2H),2.09(dd,J=14.4,5.2Hz,1H),1.99–1.77(m,5H),1.73–1.62(m,2H),1.56(dd,J=11.0,2.3Hz,1H),1.46(dd,J=10.9,2.4Hz,1H).13C NMR(100MHz,CDCl3)δ:163.93,161.47,154.44,149.22,147.04,142.99,138.24,127.53,127.45,126.59,126.56,123.57,123.02,120.10,115.96,115.74,109.11,107.44,78.00,53.86,50.81,49.60,49.11,46.18,38.16,37.31,20.83,12.56。
C32-C39和C48-C55的制备反应式如下:
上述制备方法步骤如下:
化合物23和24的合成:
将化合物10(3.00g,5.04mmol)溶于二氯甲烷(35mL)中,依次加入二氧化硒(279.7mg,2.52mmol)和70%的过氧化叔丁醇水溶液(1.94g,15.12mmol),室温反应4h,反应结束,减压蒸干,粗产品经柱层析(石油醚/乙酸乙酯=4:1)得化合物24,1.35g,收率45%。经柱层析(石油醚/乙酸乙酯=1:2)得化合物23,1.20g,收率39%。
化合物23的核磁数据:
1H NMR(400MHz,CDCl3)δ:7.70(dd,J=8.3,1.9Hz,2H),7.46(dd,J=8.3,1.8Hz,2H),7.36–7.27(m,2H),7.24–7.11(m,2H),6.89–6.72(m,2H),5.38(s,1H),5.31(s,1H),4.36(s,1H),4.32(ddd,J=10.0,5.3,1.6Hz,1H),4.28–4.16(m,1H),3.07(dd,J=7.3,4.0Hz,2H),2.95(s,2H),2.42(d,J=1.7Hz,3H),2.36(d,J=1.6Hz,3H),2.09–1.99(m,1H),1.92(d,J=11.0Hz,1H),1.76(d,J=1.8Hz,3H),1.69(dd,J=14.5,7.5Hz,1H),1.58(dd,J=11.4,5.0Hz,2H),1.21–1.13(m,1H).13C NMR(100MHz,CDCl3)δ:159.09,147.06,145.55,145.04,144.02,142.37,132.96,131.98,129.88,128.99,128.27,127.64,121.39,120.25,112.34,77.20,75.47,68.61,57.99,47.85,44.68,44.58,37.94,21.73,21.60,20.73,12.84。
化合物24的核磁数据:
1H NMR(400MHz,CDCl3)δ:7.67(dd,J=16.2,8.0Hz,4H),7.30(dd,J=8.0,5.1Hz,4H),6.79(s,2H),4.12(dd,J=10.4,8.3Hz,1H),4.01(dd,J=10.4,4.0Hz,1H),3.20–3.05(m,2H),2.43(d,J=7.5Hz,6H),2.16(dt,J=13.7,5.0Hz,1H),2.08–1.97(m,2H),1.93–1.79(m,5H),1.62(dd,J=12.9,5.1Hz,1H),1.53(td,J=12.8,5.0Hz,1H),1.34(qd,J=12.9,5.3Hz,1H),1.04(s,3H).13C NMR(101MHz,CDCl3)δ218.78,147.38,145.59,145.22,143.46,141.28,132.93,132.44,130.00,129.86,128.91,128.36,127.83,122.02,120.95,67.32,50.57,50.42,50.15,48.44,48.34,44.09,36.53,22.27,21.78,21.70,19.78,12.76.
化合物25的合成:
将化合物23(1.20g,1.96mmol)和叠氮化钠(383.0mg,5.89mmol)溶于无水的N,N-二甲基甲酰胺(20mL)。在氮气保护下,80℃反应3h,反应结束后,加入20mL水,水相用乙酸乙酯(3×65mL)萃取,合并有机相,依次用水(3×15mL)、饱和食盐水(4×15mL)洗,有机相用无水硫酸钠干燥,减压蒸干,粗产品经柱层析(石油醚/乙酸乙酯=2:1-1:1)得白色固体即化合物25,670.8mg。产率为71%。
1H NMR(400MHz,CDCl3)δ:7.73(d,J=8.0Hz,2H),7.33(d,J=8.0Hz,2H),7.00–6.72(m,2H),5.50(s,1H),5.43(s,1H),4.51(s,1H),3.65(dd,J=12.6,8.5Hz,1H),3.51(dd,J=12.6,4.5Hz,1H),3.16(t,J=9.3Hz,2H),3.08(dd,J=8.6,4.5Hz,1H),2.46(s,3H),2.13(dt,J=15.0,4.0Hz,1H),2.04(s,3H),1.99(d,J=10.9Hz,2H),1.87–1.75(m,1H),1.73–1.51(m,2H),1.23(d,J=11.4Hz,1H).13C NMR(100MHz,CDCl3)δ:158.91,147.37,145.51,143.83,143.54,133.18,129.89,128.84,128.57,121.75,120.50,112.45,77.57,75.63,59.00,49.96,48.43,45.07,44.06,37.84,21.88,20.88,13.00.
化合物26的合成:
将化合物24(1.35g,2.27mmol)和叠氮化钠(442.4mg,6.81mmol)溶于无水的N,N-二甲基甲酰胺(22mL)。在氮气保护下,80℃反应3h,反应完毕后,加入22mL水,水相用乙酸乙酯(3×70mL)萃取,合并有机相,依次用水(3×15mL)、饱和食盐水(4×18mL)洗,用无水硫酸钠干燥有机相,减压蒸干,粗产品经柱层析(石油醚/乙酸乙酯=4:1)得白色固体即化合物26,730.0mg。产率为69%。
1H NMR(400MHz,CDCl3)δ:7.70(d,J=8.3Hz,2H),7.30(d,J=8.1Hz,2H),6.83(s,2H),3.50(dd,J=12.7,8.0Hz,1H),3.42(dd,J=12.7,4.7Hz,1H),3.25(dd,J=12.3,5.1Hz,1H),2.99(dd,J=7.9,4.7Hz,1H),2.44(s,3H),2.24–2.15(m,1H),2.09–1.96(m,6H),1.93–1.85(m,1H),1.68–1.55(m,2H),1.44–1.32(m,1H),1.08(s,3H).13C NMR(100MHz,CDCl3)δ:218.97,147.48,145.47,143.31,133.04,129.82,128.63,128.47,121.94,120.95,50.88,50.54,50.44,50.25,48.57,48.50,44.26,36.70,22.36,21.77,19.85,12.97.
化合物C32的制备:
将化合物25(70mg,0.15mmol)、苯乙炔(30.6mg,0.30mmol)、醋酸铜(36.0mg,0.23mmol)、抗坏血酸钠(59.4mg,0.30mmol)、水(2.5mL)和四氢呋喃(10mL)混合,反应10h,反应结束,加入12mL水,水相用乙酸乙酯(3×20mL)萃取,合并有机相,依次用水(6mL)、饱和食盐水(2×9mL)洗,用无水硫酸钠干燥有机相,减压蒸干,未经进一步纯化,粗产品溶于无水的二氯甲烷(8mL),加入戴斯-马丁氧化剂(127.2mg,0.30mmol),室温反应4h,反应完毕后,加入10mL水,水相用二氯甲烷(3×18mL)萃取,合并有机相,依次用水(8mL)、饱和食盐水(2×10mL)洗,用无水硫酸钠干燥,减压蒸干,经柱层析(石油醚/乙酸乙酯=2:1)得白色固体即化合物C32,33.2mg,两步收率38%。熔点:116-118℃。
IRνmax(cm-1):3428,2933,2868,1725,1643,1622,1468,1372,1326,1168,1123,1064,849,814,547.HRMS(ESI)m/z calculated for C33H32O5N3S[M+H]+:582.2057,found:582.2055.1H NMR(400MHz,CDCl3)δ:7.93(d,J=8.0Hz,2H),7.78(s,1H),7.70(d,J=7.7Hz,2H),7.65(d,J=8.0Hz,2H),7.30(d,J=8.0Hz,3H),6.97(s,2H),6.21(s,1H),5.65(s,1H),5.53(dd,J=14.2,6.0Hz,1H),4.55(dd,J=14.2,6.6Hz,1H),3.70(t,J=6.2Hz,1H),3.42(d,J=7.4Hz,1H),2.51(s,1H),2.45(s,3H),2.27(d,J=12.7Hz,1H),1.96-1.74(m,5H),1.70(s,3H).13C NMR(100MHz,CDCl3)δ203.16,152.35,147.74,146.13,145.66,143.78,141.18,134.12,133.23,129.98,128.34,128.32,126.05,125.90,125.86,125.83,122.47,122.42,122.26,120.98,118.80,75.10,63.21,50.36,48.49,47.00,45.38,37.12,21.83,21.19,12.57,12.54.
化合物C33的制备:
制备方法同化合物C32,将苯乙炔改成4-溴苯乙炔,经柱层析(石油醚/乙酸乙酯=2:1)得白色固体即化合物C33,34.7mg,两步收率35%。熔点:139-141℃。
IRνmax(cm-1):3425,2932,2865,1724,1642,1597,1467,1454,1370,1194,1169,1094,1046,814,726,692,547.HRMS(ESI)m/z calculated for C33H31O5N3BrS[M+H]+:660.1162,found:660.1163,[M+2+H]+662.1144.
1H NMR(400MHz,CDCl3)δ:7.80–7.59(m,5H),7.52(dd,J=8.4,1.4Hz,2H),7.30(d,J=7.9Hz,2H),6.97(d,J=1.4Hz,2H),6.20(s,1H),5.64(s,1H),5.58–5.38(m,1H),4.65–4.35(m,1H),3.67(t,J=6.4Hz,1H),3.42(d,J=7.4Hz,1H),2.59(s,1H),2.45(s,3H),2.30–2.21(m,1H),2.06–1.78(m,4H),1.75(d,J=11.7Hz,1H),1.67(d,J=1.4Hz,3H).13CNMR(100MHz,CDCl3)δ:203.15,152.33,147.69,146.45,145.63,143.82,141.14,133.19,132.02,129.99,129.95,129.59,128.32,127.45,122.20,122.04,121.75,120.94,118.78,75.06,63.20,50.35,48.42,46.96,45.32,37.07,21.86,21.16,12.48.
化合物C34的制备:
制备方法同化合物C32,将苯乙炔改成4-甲氧基苯乙炔,经柱层析(石油醚/乙酸乙酯=2:1)得白色固体即化合物C34,36.7mg,两步收率40%。熔点:141-144℃。
IRνmax(cm-1):3426,2931,2863,1724,1643,1618,1499,1467,1370,1249,1171,1093,1046,834,814,719,547.HRMS(ESI)m/z calculated for C34H34O6N3S[M+H]+:612.2163,found:612.2163.1H NMR(400MHz,CDCl3)δ:7.80-7.61(m,4H),7.55(d,J=1.2Hz,1H),7.24(d,J=2.2Hz,2H),6.94(d,J=1.9Hz,2H),6.92-6.83(m,2H),6.14(s,1H),5.60(s,1H),5.48(dd,J=14.1,5.7Hz,1H),4.44(dd,J=14.2,7.1Hz,1H),3.78(d,J=1.2Hz,3H),3.61(t,J=6.5Hz,1H),3.39(d,J=7.2Hz,1H),3.18(s,1H),2.40(s,3H),2.32-2.14(m,1H),2.06-1.76(m,4H),1.68(d,J=11.3Hz,1H),1.56(s,3H).13C NMR(100MHz,CDCl3)δ:203.21,159.61,152.41,147.61,147.27,145.54,143.98,141.18,133.15,129.93,129.86,128.28,127.18,123.25,122.04,120.86,120.82,118.63,114.29,74.91,63.20,55.41,50.37,48.34,46.91,45.15,37.04,21.80,21.10,12.34.
化合物C35的制备:
制备方法同化合物C32,将苯乙炔改成2-乙炔吡啶,经柱层析(石油醚/乙酸乙酯=1:2)得白色固体即化合物C35,28.0mg,两步收率32%。熔点:127-128℃。
IRνmax(cm-1):3425,2930,2865,1723,1642,1598,1470,1421,1370,1222,1169,1093,1047,784,723,547.HRMS(ESI)m/z calculated for C32H31O5N4S[M+H]+:583.2010,found:583.2009.1H NMR(400MHz,CDCl3)δ:8.52(ddd,J=4.9,1.8,0.9Hz,1H),8.08(d,J=6.9Hz,2H),7.74(td,J=7.7,1.8Hz,1H),7.71-7.65(m,2H),7.28(d,J=8.0Hz,2H),7.19(ddd,J=7.6,4.8,1.2Hz,1H),6.93(d,J=1.5Hz,2H),6.16(s,1H),5.60(s,1H),5.50(dd,J=14.2,6.1Hz,1H),4.50(dd,J=14.1,6.6Hz,1H),3.67(t,J=6.3Hz,1H),3.42(d,J=7.4Hz,1H),3.13(s,1H),2.41(s,3H),2.23(ddd,J=14.2,6.9,3.8Hz,1H),1.96-1.77(m,4H),1.72(d,J=11.2Hz,1H),1.62(s,3H).13C NMR(100MHz,CDCl3)δ:203.05,152.38,150.22,149.40,147.90,147.74,145.52,143.75,141.11,136.99,133.12,129.92,129.77,128.38,123.82,122.91,122.18,120.83,120.38,118.67,74.96,63.11,50.19,48.38,46.92,45.23,37.11,21.82,21.16,12.41.
化合物C36的制备:
制备方法同化合物C32,将苯乙炔改成4-三氟甲基苯乙炔,经柱层析(石油醚/乙酸乙酯=2:1)得白色固体即化合物C36,35.1mg,两步收率36%。熔点119-121℃。
IRνmax(cm-1):3416,2933,2866,1724,1643,1597,1467,1371,1194,1168,1093,1046,815,765,695,547.HRMS(ESI)m/z calculated for C34H31O5N3F3S[M+H]+:650.1931,found:650.1934.1H NMR(400MHz,CDCl3)δ:7.84-7.76(m,2H),7.69(q,J=5.2,4.0Hz,3H),7.40(t,J=7.6Hz,2H),7.34-7.28(m,2H),6.99(q,J=8.1Hz,2H),6.20(s,1H),5.63(s,1H),5.52(dd,J=14.1,5.9Hz,1H),4.51(dd,J=14.1,6.8Hz,1H),3.67(t,J=6.3Hz,1H),3.42(d,J=7.3Hz,1H),2.66(s,1H),2.43(s,3H),2.30-2.22(m,1H),1.96-1.71(m,5H),1.64(s,3H).13C NMR(101MHz,CDCl3)δ:203.16,152.43,147.74,147.47,145.55,143.92,141.16,133.26,130.65,129.96,129.90,128.91,128.35,128.33,128.20,125.91,122.20,121.59,120.91,118.66,75.07,63.21,50.44,48.38,47.00,45.33,37.09,21.83,21.20,12.44.
化合物C37的制备:
制备方法同化合物C32,将苯乙炔改成4-甲基苯乙炔,经柱层析(石油醚/乙酸乙酯=2:1)得白色固体即化合物C37,4.0mg,两步收率38%。熔点:171-174℃。
IRνmax(cm-1):3424,2929,2865,1724,1643,1467,1195,1169,1093,1046,814,782,720,546.HRMS(ESI)m/z calculated for C34H34O5N3S[M+H]+:596.2214,found:596.2214.1HNMR(400MHz,CDCl3)δ:7.69(d,J=2.6Hz,2H),7.67(d,J=2.4Hz,2H),7.63(s,1H),7.27(d,J=8.1Hz,2H),7.20(d,J=7.9Hz,2H),6.98(q,J=8.2Hz,2H),6.18(s,1H),5.62(s,1H),5.51(dd,J=14.1,5.8Hz,1H),4.48(dd,J=14.2,7.0Hz,1H),3.65(t,J=6.4Hz,1H),3.42(d,J=7.3Hz,1H),2.94(s,1H),2.42(s,3H),2.36(s,3H),2.30-2.22(m,1H),2.09-1.77(m,4H),1.72(d,J=11.1Hz,1H),1.60(s,3H).13C NMR(100MHz,CDCl3)δ:203.20,152.40,147.67,147.50,145.54,143.96,141.15,138.02,133.20,129.94,129.87,129.56,128.31,127.75,125.80,122.12,121.24,120.88,118.65,74.99,63.21,50.41,48.35,46.95,45.23,37.05,21.82,21.37,21.15,12.36.
化合物C38的制备:
制备方法同化合物C32,将苯乙炔改成4-氯苯乙炔,经柱层析(石油醚/乙酸乙酯=2:1)得白色固体即化合物C38,32.3mg,两步收率35%。熔点:135-136℃。
IRνmax(cm-1):3424,2932,2865,1723,1642,1597,1484,1467,1370,1194,1169,1093,1046,833,814,718,547.HRMS(ESI)m/z calculated for C34H31O5N3ClS[M+H]+:616.1667,found:616.1667.1H NMR(400MHz,CDCl3)δ:7.92-7.57(m,5H),7.43-7.33(m,2H),7.29(d,J=8.1Hz,2H),6.96(s,2H),6.19(s,1H),5.63(s,1H),5.51(dd,J=14.2,6.0Hz,1H),4.49(dd,J=14.2,6.7Hz,1H),3.67(t,J=6.3Hz,1H),3.48-3.29(m,1H),2.61(s,1H),2.44(s,3H),2.33-2.15(m,1H),2.08-1.77(m,4H),1.74(d,J=11.2Hz,1H),1.66(s,3H).13CNMR(100MHz,CDCl3)δ:203.16,152.33,147.69,146.43,145.63,143.83,141.15,133.89,133.19,129.98,129.96,129.14,129.08,128.32,127.17,122.20,121.73,120.94,118.77,75.06,63.21,50.36,48.42,46.97,45.32,37.08,21.86,21.16,12.48.
化合物C39的制备:
制备方法同化合物C32,将苯乙炔改成4-氟苯乙炔,经柱层析(石油醚/乙酸乙酯=2:1)得白色固体即化合物C39,32.4mg,两步收率36%。熔点:184-186℃。
IRνmax(cm-1):3416,2933,2868,1723,1645,1598,1498,1468,1454,1373,1220,1170,1043,842,830,754,662,529.HRMS(ESI)m/z calculated for C33H31O5N3FS[M+H]+:600.1963,found:600.1962.1H NMR(400MHz,CDCl3)δ:7.86-7.72(m,2H),7.70(d,J=8.3Hz,2H),7.64(s,1H),7.30(d,J=8.1Hz,2H),7.09(t,J=8.7Hz,2H),6.98(s,2H),6.21(s,1H),5.64(s,1H),5.53(dd,J=14.1,5.9Hz,1H),4.50(dd,J=14.2,6.8Hz,1H),3.68(t,J=6.4Hz,1H),3.49-3.34(m,1H),2.44(s,4H),2.35-2.17(m,1H),2.10-1.80(m,4H),1.75(d,J=11.2Hz,1H),1.66(s,3H).13C NMR(100MHz,CDCl3)δ:203.15,163.96,161.50,152.36,147.70,146.64,145.62,143.89,141.15,133.21,129.98,128.37,128.33,127.70,127.62,126.87,122.19,121.40,120.93,118.75,115.96,115.74,75.09,63.23,50.39,48.41,46.98,45.33,37.08,21.86,21.18,12.47.
化合物C48的制备:
将化合物26(50mg,0.11mmol)、苯乙炔(22.4mg,0.22mmol)、醋酸铜(33.0mg,0.17mmol)、抗坏血酸钠(43.6mg,0.22mmol)、水(2.5mL)和四氢呋喃(10mL)混合,反应10h,反应结束,加入12mL水,用乙酸乙酯(3×20mL)萃取,合并有机相,依次用水(6mL)、饱和食盐水(2×10mL)洗,用无水硫酸钠干燥,减压蒸干,经柱层析(石油醚/乙酸乙酯=3:1)得白色固体即化合物C48,36.2mg,收率58%。熔点:223-226℃。
IRνmax(cm-1):2957,2931,1739,1598,1469,1404,1364,1164,1095,1050,890,854,829,751,694,663,593,538.HRMS(ESI)m/z calculated for C33H34O4N3S[M+H]+:568.2265,found:568.2264.1H NMR(400MHz,CDCl3)δ:7.82-7.76(m,2H),7.73-7.66(m,2H),7.51-7.36(m,2H),7.35-7.31(m,1H),7.30(s,1H),7.28(s,1H),7.26(s,1H),6.77(q,J=8.1Hz,2H),4.71(dd,J=14.2,6.4Hz,1H),4.60(dd,J=14.2,5.3Hz,1H),3.51(t,J=5.9Hz,1H),2.83(dd,J=12.3,5.1Hz,1H),2.44(s,3H),2.27(dd,J=11.4,3.5Hz,1H),2.20-2.04(m,2H),1.99(s,1H),1.96(s,3H),1.91-1.84(m,1H),1.71-1.52(m,2H),1.35(qd,J=12.6,5.9Hz,1H),1.07(s,3H).13C NMR(100MHz,CDCl3)δ:218.52,147.91,147.60,145.59,143.71,143.04,133.19,130.42,129.93,129.15,128.92,128.36,128.32,125.79,122.01,121.34,120.68,51.28,51.07,50.67,49.30,48.76,48.33,43.50,36.58,22.39,21.82,19.82,12.94.
化合物C49的制备:
制备方法同化合物C48,将苯乙炔改成4-溴苯乙炔,经柱层析(石油醚/乙酸乙酯=3:1)得白色固体即化合物C49,37.7mg,收率53%。熔点:119-123℃。
IRνmax(cm-1):2925,2868,1739,1597,1456,1370,1197,1177,1093,1046,839,814,728,552.HRMS(ESI)m/z calculated for C33H33O4N3BrS[M+H]+:646.1370,found:[M+H]+646.1374,[M+2+H]+648.1379.1H NMR(400MHz,CDCl3)δ:7.77-7.62(m,4H),7.55-7.45(m,2H),7.29(dd,J=8.7,2.8Hz,3H),6.90-6.71(m,2H),4.72(dd,J=14.2,6.3Hz,1H),4.59(dd,J=14.2,5.5Hz,1H),3.51(t,J=5.9Hz,1H),2.84(dd,J=12.3,5.2Hz,1H),2.46(s,3H),2.26(dd,J=11.3,3.5Hz,1H),2.17-2.06(m,2H),2.00(s,1H),1.95(s,3H),1.92-1.83(m,1H),1.74-1.51(m,2H),1.36(qd,J=12.7,5.9Hz,1H),1.08(s,3H).13C NMR(100MHz,CDCl3)δ:218.38,147.52,146.87,145.66,143.68,142.99,133.16,132.01,129.95,129.36,129.20,128.29,127.34,122.14,122.01,121.36,120.89,51.27,51.04,50.65,49.36,48.69,48.33,43.50,36.56,22.37,21.82,19.80,12.94。
化合物C50的制备:
制备方法同化合物C48,将苯乙炔改成4-甲氧基苯乙炔,经柱层析(石油醚/乙酸乙酯=3:1)得白色固体即化合物C50,40.1mg,收率61%。熔点:179-180℃。
IRνmax(cm-1):2924,2848,1736,1618,1597,1561,1500,1457,1367,1248,1198,1093,1032,888,838,721,664,551.HRMS(ESI)m/z calculated for C34H36O5N3S[M+H]+:598.2370,found:598.2372.1H NMR(400MHz,CDCl3)δ:7.68(dd,J=8.6,3.2Hz,4H),7.27(s,1H),7.25(s,1H),7.21(s,1H),7.01-6.85(m,2H),6.84-6.66(m,2H),4.66(dd,J=14.2,6.5Hz,1H),4.52(dd,J=14.2,5.5Hz,1H),3.79(s,3H),3.48(t,J=6.0Hz,1H),2.84(dd,J=12.2,5.1Hz,1H),2.42(s,3H),2.22(dd,J=11.4,3.5Hz,1H),2.16-1.97(m,2H),1.96(s,1H),1.91(s,3H),1.88-1.75(m,1H),1.66-1.47(m,2H),1.46-1.26(m,1H),1.04(s,3H).
13C NMR(100MHz,CDCl3)δ:218.51,159.70,147.73,147.52,145.57,143.66,143.11,133.15,129.90,129.09,128.32,127.06,123.11,121.94,121.28,119.85,114.28,55.39,51.25,51.02,50.60,49.19,48.67,48.25,43.44,36.55,22.36,21.79,19.78,12.85.
化合物C51的制备:
制备方法同化合物C48,将苯乙炔改成2-乙炔吡啶,经柱层析(石油醚/乙酸乙酯=1:1)得白色固体即化合物C51,30.7mg,收率49%。熔点:238-240℃。
IRνmax(cm-1):2955,2927,1739,1601,1473,1367,1165,1095,1046,853,811,751,664,538.HRMS(ESI)m/z calculated for C32H33O4N4S[M+H]+:569.2217,found:569.2218.1HNMR(400MHz,CDCl3)δ:8.53(ddd,J=4.9,1.7,0.9Hz,1H),8.13(dt,J=7.9,1.1Hz,1H),7.85(s,1H),7.77(dd,J=7.7,1.8Hz,1H),7.75-7.68(m,2H),7.28(d,J=8.0Hz,2H),7.22(ddd,J=7.6,4.8,1.2Hz,1H),6.80(d,J=2.0Hz,2H),4.69(dd,J=14.2,8.0Hz,1H),4.45(dd,J=14.2,4.9Hz,1H),3.56(dd,J=8.0,4.9Hz,1H),3.02(dd,J=12.2,5.2Hz,1H),2.42(s,3H),2.26-1.98(m,3H),1.95(s,1H),1.91(s,3H),1.73-1.49(m,3H),1.36(qd,J=12.6,5.8Hz,1H),1.00(s,3H).13C NMR(100MHz,CDCl3)δ:218.47,150.02,149.50,148.62,147.60,145.55,143.33,142.79,137.01,133.03,129.88,128.82,128.54,123.08,122.65,122.30,121.30,120.32,51.23,50.99,50.54,49.07,48.63,48.17,43.40,36.60,22.40,21.82,19.78,12.72.
化合物C52的制备:
制备方法同化合物C48,将苯乙炔改成4-三氟甲基苯乙炔,经柱层析(石油醚/乙酸乙酯=3:1)得白色固体即化合物C52,40.1mg,收率58%。熔点:139-141℃。
IRνmax(cm-1):2928,1741,1622,1469,1372,1326,1166,1124,1064,888,849,719,552.HRMS(ESI)m/z calculated for C34H33O4N3F3S[M+H]+:636.2138,found:636.2136.1HNMR(400MHz,CDCl3)δ:7.89(d,J=8.1Hz,2H),7.70-7.65(m,2H),7.62(d,J=8.2Hz,2H),7.37(s,1H),7.27(d,J=6.4Hz,2H),6.78(d,J=8.1Hz,1H),6.74(s,1H),4.74(dd,J=14.2,6.2Hz,1H),4.62(dd,J=14.2,5.5Hz,1H),3.51(t,J=5.8Hz,1H),2.81(dd,J=12.3,5.1Hz,1H),2.43(s,3H),2.27(dd,J=11.3,3.6Hz,1H),2.11(dt,J=18.8,3.5Hz,2H),1.99(s,1H),1.96(s,3H),1.90(dd,J=11.3,1.5Hz,1H),1.71-1.50(m,2H),1.34(qd,J=12.6,6.0Hz,1H),1.07(s,3H).13C NMR(100MHz,CDCl3)δ:218.33,147.55,146.54,145.71,143.73,142.95,133.86,133.16,130.19,129.94,129.87,129.26,128.27,128.21,125.95,125.92,125.88,125.84,125.80,125.50,122.80,122.05,121.66,121.40,51.29,51.05,50.68,49.45,48.72,48.38,43.52,36.56,22.36,21.78,19.79,12.99.
化合物C53的制备:
制备方法同化合物C48,将苯乙炔改成4-甲基苯乙炔,经柱层析(石油醚/乙酸乙酯=3:1)得白色固体即化合物C53,41.0mg,收率64%。熔点:141-143℃。
IRνmax(cm-1):2925,2868,1740,1597,1467,1370,1177,1093,1047,841,814,720,552.HRMS(ESI)m/z calculated for C34H36O4N3S[M+H]+:582.2421,found:582.2420.1H NMR(400MHz,CDCl3)δ:7.68(dd,J=10.9,8.0Hz,4H),7.30-7.27(m,3H),7.21(d,J=7.9Hz,2H),6.93-6.54(m,2H),4.69(dd,J=14.2,6.5Hz,1H),4.56(ddd,J=14.0,5.5,1.6Hz,1H),3.51(t,J=5.9Hz,1H),2.85(dd,J=12.3,5.1Hz,1H),2.44(s,3H),2.36(s,3H),2.31-2.19(m,1H),2.11(ddd,J=18.6,11.9,4.2Hz,2H),1.98(s,1H),1.93(d,J=1.6Hz,3H),1.85(d,J=11.3Hz,1H),1.69-1.51(m,2H),1.46-1.28(m,1H),1.06(s,3H).13C NMR(100MHz,CDCl3)δ:218.53,147.95,147.55,145.56,143.66,143.08,138.15,133.17,129.90,129.56,129.08,128.35,127.58,125.68,121.98,121.29,120.29,51.26,51.04,50.62,49.22,48.70,48.27,43.45,36.56,22.38,21.80,21.35,19.79,12.86.
化合物C54的制备:
制备方法同化合物C48,将苯乙炔改成4-氯苯乙炔,经柱层析(石油醚/乙酸乙酯=3:1)得白色固体即化合物C54,41.1mg,收率62%。熔点:117-119℃。
IRνmax(cm-1):2926,2868,1740,1597,1456,1370,1178,1093,1047,839,814,663,552.HRMS(ESI)m/z calculated for C33H33O4N3ClS[M+H]+:602.1875,found:602.1873.1HNMR(400MHz,CDCl3)δ:7.82-7.57(m,4H),7.35(d,J=8.5Hz,2H),7.29(dd,J=7.8,3.2Hz,3H),6.80(d,J=8.1Hz,1H),6.75(d,J=8.1Hz,1H),4.72(dd,J=14.2,6.4Hz,1H),4.59(dd,J=14.2,5.6Hz,1H),3.51(t,J=5.9Hz,1H),2.85(dd,J=12.3,5.2Hz,1H),2.45(s,3H),2.26(dd,J=11.3,3.6Hz,1H),2.20-2.06(m,2H),2.00(s,1H),1.95(s,3H),1.89(dd,J=11.4,1.5Hz,1H),1.74-1.53(m,2H),1.36(qd,J=12.7,5.9Hz,1H),1.08(s,3H).13C NMR(100MHz,CDCl3)δ:218.39,147.52,146.85,145.66,143.68,143.00,133.98,133.16,129.94,129.20,129.06,128.92,128.28,127.05,122.00,121.35,120.86,51.27,51.03,50.65,49.35,48.69,48.33,43.49,36.56,22.36,21.81,19.80,12.93。
化合物C55的制备:
制备方法同化合物C48,将苯乙炔改成4-氟苯乙炔,经柱层析(石油醚/乙酸乙酯=3:1)得白色固体即化合物C55,40.6mg,收率63%。熔点:180-182℃。
IRνmax(cm-1):2926,2868,1740,1597,1561,1497,1467,1370,1223,1178,1094,1046,888,841,771,716,813,552.HRMS(ESI)m/z calculated for C33H33O4N3FS[M+H]+:586.2170,found:586.2169.1H NMR(400MHz,CDCl3)δ:7.98-7.73(m,2H),7.69(d,J=8.2Hz,2H),7.30(d,J=7.8Hz,3H),7.08(t,J=8.7Hz,2H),6.80(d,J=8.1Hz,1H),6.75(d,J=8.1Hz,1H),4.72(dd,J=14.2,6.4Hz,1H),4.58(dd,J=14.2,5.5Hz,1H),3.52(t,J=6.0Hz,1H),2.86(dd,J=12.2,5.1Hz,1H),2.45(s,3H),2.26(dd,J=11.4,3.5Hz,1H),2.19-2.05(m,2H),2.00(s,1H),1.95(s,3H),1.91-1.84(m,1H),1.72-1.54(m,2H),1.36(qd,J=12.7,6.0Hz,1H),1.07(s,3H).13C NMR(101MHz,CDCl3)δ:218.41,163.92,161.46,147.50,147.01,145.64,143.66,143.03,133.13,129.92,129.17,128.27,127.55,127.47,126.64,126.61,121.95,121.31,120.51,115.92,115.71,51.25,51.01,50.62,49.28,48.66,48.29,43.46,36.54,22.34,21.78,19.77,12.89.
C40-C47的制备反应式如下:
上述制备步骤如下:
化合物29的合成:
将化合物17(3.50g,8.16mmol)溶于二氯甲烷(45mL)中,依次加入二氧化硒(452.9mg,4.08mmol)和70%的过氧化叔丁醇水溶液(3.15g,24.48mmol),室温反应4h,反应结束,减压蒸干,粗产品经柱层析(石油醚/乙酸乙酯=4:1)得白色固体即化合物29,2.83g,收率78%。
1H NMR(400MHz,CDCl3)δ:6.81(d,J=8.0Hz,1H),6.67(d,J=8.0Hz,1H),5.45(s,1H),5.41(d,J=1.3Hz,1H),4.53(s,1H),3.76(s,1H),3.63(s,4H),3.35(d,J=7.7Hz,1H),3.06(s,1H),2.14(s,3H),2.11–2.03(m,1H),2.03–1.97(m,1H),1.85–1.60(m,3H),1.44–1.33(m,1H),1.01(s,9H),0.21(d,J=1.4Hz,6H).13C NMR(100MHz,CDCl3)δ:173.56,159.06,152.58,140.52,138.05,126.69,119.84,117.57,112.34,77.64,76.32,59.79,54.16,52.12,45.22,44.42,37.81,25.88,21.06,18.35,13.21,-4.13.
化合物30的合成:
在氮气保护下,将化合物29(2.83g,6.36mmol)溶于无水的四氢呋喃(45mL)中,在冰水浴的条件下分批加入四氢铝锂(483.3mg,12.72mmol),加完后移除冰水浴,在室温反应4h,反应结束,缓慢加入30mL冰水,水相用乙酸乙酯(3×60mL)萃取,合并有机相,依次用水(2×20mL)、饱和食盐水(2×20mL)洗,用无水硫酸钠干燥有机相,减压蒸干,粗产物经柱层析(石油醚/乙酸乙酯=4:1)得白色固体即化合物30,2.33g,收率88%。
1H NMR(400MHz,CDCl3)δ:6.77(d,J=8.0Hz,1H),6.61(d,J=7.9Hz,1H),5.80(s,1H),5.46(s,1H),5.38(d,J=16.8Hz,2H),4.56(s,1H),4.05(s,1H),3.70(t,J=10.8Hz,1H),3.56(d,J=10.7Hz,1H),3.16(dd,J=10.6,2.8Hz,1H),3.07(d,J=7.5Hz,1H),2.15(s,3H),2.13–2.06(m,1H),2.02–1.88(m,1H),1.82–1.57(m,3H),1.33(d,J=10.8Hz,1H),1.02(s,9H),0.21(d,J=3.6Hz,6H).13C NMR(100MHz,CDCl3)δ:158.10,152.70,142.71,136.65,125.96,119.57,116.85,112.69,77.80,76.20,59.81,58.83,51.94,45.14,44.02,37.79,25.91,20.68,18.35,12.87,-4.09,-4.11.
化合物31的合成:
将化合物30(2.33g,5.59mmol)溶于无水的二氯甲烷(40mL)中,分别加入二异丙基乙胺(1.08g,8.39mmol)、对甲苯磺酰氯(1.06g,5.59mmol)、4-二甲氨基吡啶(136.4mg,1.12),在室温反应10h,反应结束,减压蒸干,粗产物经柱层析(石油醚/乙酸乙酯=2:1)得白色固体即化合物31,2.68g。收率为84%。
1H NMR(400MHz,CDCl3)δ:7.58–7.52(m,2H),7.23(dd,J=8.5,2.3Hz,2H),6.76(d,J=8.0Hz,1H),6.62(d,J=8.0Hz,1H),5.41(d,J=2.0Hz,1H),5.34(s,1H),4.41(d,J=1.8Hz,1H),4.29(qd,J=9.9,5.7Hz,2H),3.14(dd,J=11.2,5.4Hz,3H),3.04(d,J=7.8Hz,1H),2.40(d,J=2.0Hz,3H),2.10–2.00(m,1H),1.96(d,J=11.2Hz,1H),1.92(s,3H),1.78–1.53(m,3H),1.26(dd,J=10.7,1.9Hz,1H),1.01(s,9H),0.20(d,J=11.2Hz,6H).13C NMR(100MHz,CDCl3)δ:159.21,152.61,144.83,141.49,137.28,132.28,129.80,127.82,126.31,119.76,117.23,112.26,77.36,75.71,68.90,58.21,47.90,44.80,44.17,37.99,25.86,21.68,20.91,18.29,13.04,-4.08,-4.23.
化合物32的合成:
将化合物31(2.68g,4.69mmol)和叠氮化钠(914.6mg,14.07mmol)溶于无水的N,N-二甲基甲酰胺(50mL)。在氮气保护下,80℃反应3h,反应结束后,加入50mL水,水相用乙酸乙酯(3×90mL)萃取,合并有机相,依次用水(3×18mL)、饱和食盐水(4×25mL)洗,用无水硫酸钠干燥有机相,减压蒸干,粗产品经柱层析(石油醚/乙酸乙酯=3:1)得白色固体即化合物32,1.49g。产率为72%。
1H NMR(400MHz,CDCl3)δ:6.80(d,J=8.0Hz,1H),6.65(d,J=8.0Hz,1H),5.45(s,1H),5.39(s,1H),4.47(s,1H),3.77(d,J=2.9Hz,1H),3.66(dd,J=12.5,8.4Hz,1H),3.52(dd,J=12.5,4.6Hz,1H),3.33(s,1H),3.17–2.99(m,2H),2.18(s,3H),2.15–2.04(m,1H),2.03–1.95(m,1H),1.86–1.55(m,3H),1.27(dd,J=10.8,1.8Hz,1H),1.02(s,9H),0.21(d,J=5.2Hz,6H).13C NMR(100MHz,CDCl3)δ:158.60,152.75,143.09,136.89,125.86,119.82,117.22,112.43,77.40,75.75,58.81,50.27,48.46,44.81,43.75,37.91,25.86,20.88,18.30,13.07,-4.11,-4.20.
化合物C40的制备:
将化合物32(70mg,0.16mmol)、苯乙炔(32.6mg,0.32mmol)、醋酸铜(48.0mg,0.24mmol)、抗坏血酸钠(63.4mg,0.32mmol)、水(2mL)和四氢呋喃(10mL)混合,室温反应11h,反应结束,加入14mL水,水相用乙酸乙酯(3×24mL)萃取,合并有机相,依次用水(8mL)、饱和食盐水(2×12mL)洗,用无水硫酸钠干燥,减压蒸干,未经进一步纯化,粗产品溶于无水的二氯甲烷(10mL),加入戴斯-马丁氧化剂(135.7mg,0.32mmol),室温反应4.5h,反应完毕后,加入11mL水,用二氯甲烷(3×24mL)萃取,合并有机相,依次用水(10mL)、饱和食盐水(2×10mL)洗,用无水硫酸钠干燥,减压蒸干,未经进一步纯化,溶于无水的四氢呋喃(10mL)中,加入三水合四丁基氟化铵(55.6mg,0.18mmol),室温反应1h,反应结束,加入10mL水,用乙酸乙酯(3×25mL)萃取,合并有机相,依次用水(8mL)、饱和食盐水(3×12mL)洗,用无水硫酸钠干燥,减压蒸干,经柱层析(石油醚/乙酸乙酯=1:1)得白色固体即化合物C40,2.0mg,三步总收率45%。熔点:165-167℃。
IRνmax(cm-1):3387,2932,2864,1722,1642,1601,1464,1264,1081,1054,821,765,694.HRMS(ESI)m/z calculated for C26H26O3N3[M+H]+:428.1969,found:428.1969.1H NMR(400MHz,MeOD)δ:7.95(d,J=2.4Hz,1H),7.72(d,J=7.5Hz,2H),7.39(td,J=7.6,1.7Hz,2H),7.35–7.19(m,1H),6.90(d,J=8.0Hz,1H),6.69(d,J=8.0Hz,1H),6.17(s,1H),5.58(s,1H),5.54(d,J=5.5Hz,1H),4.62(ddd,J=14.5,8.9,2.2Hz,1H),3.68(dd,J=8.9,5.4Hz,1H),3.48(d,J=6.8Hz,1H),2.45–2.23(m,1H),1.88–1.76(m,4H),1.67(d,J=11.1Hz,1H),1.50(s,3H).13C NMR(100MHz,MeOD)δ:205.02,155.80,154.52,148.54,144.27,134.05,131.60,129.93,129.27,126.63,124.06,123.65,121.52,118.09,114.59,75.63,65.21,51.06,50.05,47.76,45.76,38.26,21.96,11.64.
化合物C41的制备:
制备方法同化合物C40,将苯乙炔改成4-溴苯乙炔,经柱层析(石油醚/乙酸乙酯=1:1)得白色固体即化合物C41,34.8mg,三步总收率43%。熔点:157-160℃。
IRνmax(cm-1):3405,2931,2864,1722,1642,1602,1454,1336,1263,1179,1070,1010,972,821,652,514.HRMS(ESI)m/z calculated for C26H25O3N3Br[M+H]+:506.1074,found:[M+H]+506.1072,[M+2+H]+508.1059.1H NMR(400MHz,MeOD)δ:8.00(s,1H),7.65(d,J=8.4Hz,2H),7.55(d,J=8.3Hz,2H),6.90(d,J=8.0Hz,1H),6.68(d,J=8.0Hz,1H),6.17(s,1H),5.68–5.50(m,2H),4.62(dd,J=14.1,8.8Hz,1H),3.68(dd,J=8.7,5.5Hz,1H),3.48(d,J=7.1Hz,1H),2.32(dd,J=11.5,3.9Hz,1H),1.83(tt,J=9.4,4.1Hz,4H),1.67(d,J=11.1Hz,1H),1.51(s,3H).13C NMR(100MHz,MeOD)δ:205.03,155.82,154.54,147.42,144.23,134.06,133.08,130.84,128.32,124.02,123.90,122.92,121.54,118.10,114.62,75.64,65.21,51.04,50.10,47.78,45.77,38.28,21.97,11.65.
化合物C42的制备:
制备方法同化合物C40,将苯乙炔改成4-甲氧基苯乙炔,经柱层析(石油醚/乙酸乙酯=1:1)得白色固体即化合物C42,34.4mg,三步总收率47%。熔点:157-158℃。
IRνmax(cm-1):3394,2933,2864,1722,1642,1618,1500,1457,1249,1176,836,732,534.HRMS(ESI)m/z calculated for C27H28O4N3[M+H]+:458.2074,found:458.2076.1H NMR(400MHz,CDCl3)δ:7.65(d,J=8.7Hz,2H),7.59(s,1H),6.97–6.85(m,2H),6.81(d,J=8.0Hz,1H),6.77–6.70(m,2H),6.16(s,1H),5.61(s,1H),5.53(dd,J=14.0,5.7Hz,1H),4.44(dd,J=14.1,7.5Hz,1H),3.80(s,3H),3.60(t,J=6.7Hz,1H),3.39(d,J=5.7Hz,1H),2.21(d,J=7.8Hz,1H),1.96–1.71(m,6H),1.63(s,3H).13C NMR(100MHz,CDCl3)δ:203.99,159.67,154.02,152.67,147.24,143.12,133.47,127.24,123.12,122.83,121.07,120.64,118.44,114.50,114.40,75.27,63.76,55.46,50.36,48.94,46.88,45.29,37.13,21.28,11.56.
化合物C43的制备:
制备方法同化合物C40,将苯乙炔改成2-乙炔吡啶,经柱层析(石油醚/乙酸乙酯=1:2)得白色固体即化合物C43,27.8mg,三步总收率38%。熔点:164-166℃。
IRνmax(cm-1):3404,2932,2864,1722,1642,1602,1473,1422,1264,1054,997,822,784,742.HRMS(ESI)m/z calculated for C25H25O3N4[M+H]+:429.1921,found:429.1922.
1H NMR(400MHz,MeOD)δ:8.53(d,J=4.9Hz,1H),8.21(s,1H),8.05(d,J=7.9Hz,1H),7.90(td,J=7.8,1.7Hz,1H),7.40–7.28(m,1H),6.90(d,J=8.0Hz,1H),6.69(d,J=8.0Hz,1H),6.18(s,1H),5.64–5.53(m,2H),4.71(dd,J=14.1,8.4Hz,1H),3.72(dd,J=8.4,5.6Hz,1H),3.50(d,J=6.9Hz,1H),3.36(s,1H),2.38–2.26(m,1H),1.91–1.79(m,4H),1.69(d,J=11.1Hz,1H),1.57(s,3H).13C NMR(100MHz,MeOD)δ:205.01,155.84,154.55,150.95,150.32,148.24,144.13,138.89,134.06,125.57,124.42,123.94,121.51,121.45,118.07,114.63,75.64,65.13,51.05,50.14,47.80,45.81,38.29,21.96,11.70.
化合物C44的制备:
制备方法同化合物C40,将苯乙炔改成4-三氟甲基苯乙炔,经柱层析(石油醚/乙酸乙酯=1:1)得白色固体即化合物C44,29.4mg,三步总收率37%。熔点:160-161℃。
IRνmax(cm-1):3397,2934,2866,1724,1663,1325,1265,1167,1123,1065,849,822,733.HRMS(ESI)m/z calculated for C27H25O3N3F3[M+H]+:496.1843,found:496.1847.1HNMR(400MHz,MeOD)δ:8.13(s,1H),7.92(d,J=8.0Hz,2H),7.70(d,J=8.1Hz,2H),6.91(d,J=8.0Hz,1H),6.69(d,J=8.0Hz,1H),6.17(s,1H),5.57(q,J=6.5,5.5Hz,2H),4.66(dd,J=9.2,5.1Hz,1H),3.70(dd,J=8.7,5.7Hz,1H),3.49(d,J=7.0Hz,1H),2.42–2.24(m,1H),2.00–1.73(m,5H),1.67(d,J=11.0Hz,1H),1.52(s,3H).13C NMR(101MHz,MeOD)δ:205.03,155.85,154.53,147.03,144.21,135.54,134.07,131.35,131.02,130.70,130.38,126.96,126.91,126.87,126.83,124.70,124.25,124.01,121.57,118.13,114.64,75.66,65.22,51.02,50.15,47.79,45.77,38.28,21.96,11.66.
化合物C45的制备:
制备方法同化合物C40,将苯乙炔改成4-甲基苯乙炔,经柱层析(石油醚/乙酸乙酯=1:1)得白色固体即化合物C45,29.7mg,三步总收率42%。熔点:154-156℃。
IRνmax(cm-1):3404,2931,2865,1723,1642,1601,1453,1264,1183,1081,1054,820,519.HRMS(ESI)m/z calculated for C27H28O3N3[M+H]+:442.2125,found:442.2126.1HNMR(400MHz,MeOD)δ:7.90(s,1H),7.60(d,J=8.0Hz,2H),7.21(d,J=7.9Hz,2H),6.90(d,J=8.0Hz,1H),6.68(d,J=8.0Hz,1H),6.17(s,1H),5.67–5.49(m,2H),4.60(dd,J=14.1,8.9Hz,1H),3.67(dd,J=8.9,5.4Hz,1H),3.48(d,J=7.0Hz,1H),2.30-2.35(s,4H),1.85(ddt,J=25.4,9.6,5.8Hz,4H),1.66(d,J=11.1Hz,1H),1.49(s,3H).13C NMR(100MHz,MeOD)δ:205.04,155.81,154.57,148.65,144.31,139.31,134.05,130.53,128.79,126.59,124.09,123.30,121.51,118.06,114.58,75.64,65.24,51.09,50.04,47.78,45.78,38.28,21.97,21.30,11.62.
化合物C46的制备:
制备方法同化合物C40,将苯乙炔改成4-氯苯乙炔,经柱层析(石油醚/乙酸乙酯=1:1)得白色固体即化合物C46,28.8mg,三步总收率39%。熔点:162-165℃。
IRνmax(cm-1):3374,2931,2863,1722,1642,1601,1455,1336,1263,1092,1054,820,653,517.HRMS(ESI)m/z calculated for C26H25O3N3Cl[M+H]+:462.1579,found:462.1581.1H NMR(400MHz,MeOD)δ:7.98(s,1H),7.70(d,J=8.4Hz,2H),7.39(d,J=8.3Hz,2H),6.90(d,J=8.0Hz,1H),6.68(d,J=8.0Hz,1H),6.16(s,1H),5.65–5.48(m,2H),4.61(dd,J=14.1,8.7Hz,1H),3.68(dd,J=8.7,5.5Hz,1H),3.47(d,J=7.0Hz,1H),2.32(dt,J=12.0,2.7Hz,1H),1.96–1.73(m,4H),1.67(d,J=11.0Hz,1H),1.51(s,3H).13C NMR(100MHz,MeOD)δ:205.02,155.81,154.52,147.39,144.22,134.90,134.05,130.41,130.07,128.05,124.02,123.87,121.54,118.10,114.61,79.42,65.19,51.02,50.08,47.77,45.75,38.26,21.96,11.65.
化合物C47的制备:
制备方法同化合物C40,将苯乙炔改成4-氟苯乙炔,经柱层析(石油醚/乙酸乙酯=1:1)得白色固体即化合物C47,25.6mg,三步总收率36%。熔点:161-163℃。
IRνmax(cm-1):3405,2933,2865,1723,1643,1602,1498,1458,1337,1264,1226,1157,1055,841,815,526.HRMS(ESI)m/z calculated for C26H25O3N3F[M+H]+:446.1874,found:446.1873.1H NMR(400MHz,MeOD)δ:7.85(s,1H),7.70–7.56(m,2H),7.03(t,J=8.7Hz,2H),6.80(d,J=8.0Hz,1H),6.58(d,J=8.0Hz,1H),6.06(s,1H),5.67–5.33(m,2H),4.51(dd,J=14.0,8.7Hz,1H),3.57(dd,J=8.8,5.5Hz,1H),3.38(d,J=7.0Hz,1H),3.20(p,J=1.6Hz,1H),2.22(dt,J=12.4,2.7Hz,1H),1.82–1.64(m,4H),1.56(d,J=11.1Hz,1H),1.39(s,3H).13C NMR(100MHz,MeOD)δ:205.04,165.27,162.82,155.83,154.56,147.65,144.28,134.07,128.63,128.55,128.11,128.08,124.07,123.57,121.54,118.09,116.86,116.64,114.61,75.65,65.24,51.07,50.08,47.78,45.78,38.29,21.97,11.62.
C56-C62的制备反应式如下:
上述制备方法步骤如下:
化合物27的合成:
将化合物20(2.00g,4.54mmol)溶于二氯甲烷(35mL)中,依次加入二氧化硒(252.0mg,2.27mmol)和70%的过氧化叔丁醇水溶液(1.75g,13.62mmol),室温反应4h,反应结束,减压蒸干,粗产品经柱层析(石油醚/乙酸乙酯=4:1)得白色固体即化合物27,1.42g,收率71%。
1H NMR(400MHz,CDCl3)δ:7.68(d,J=8.2Hz,2H),7.30(d,J=8.2Hz,2H),6.65(t,J=8.5Hz,1H),6.58(t,J=7.5Hz,1H),4.17–4.08(m,1H),4.04(dd,J=10.4,3.9Hz,1H),3.17–3.05(m,2H),2.42(s,3H),2.15(dd,J=12.9,5.1Hz,1H),2.09–1.99(m,2H),1.95(s,3H),1.92–1.86(m,2H),1.58(dtd,J=17.8,12.7,5.1Hz,2H),1.38–1.25(m,1H),1.23(s,1H),1.05(s,3H).13C NMR(101MHz,CDCl3)δ:221.23,153.50,145.16,140.36,136.09,132.46,129.96,127.90,121.51,120.63,114.26,67.86,50.66,50.51,50.12,48.47,48.02,44.20,36.80,25.83,22.57,21.67,19.79,11.90.
化合物28的合成:
将化合物27(1.42g,3.22mmol)和叠氮化钠(627.9mg,9.66mmol)溶于无水的N,N-二甲基甲酰胺(24mL)。在氮气保护下,80℃反应2.5h,反应结束后,加入30mL水,水相用乙酸乙酯(3×65mL)萃取,合并有机相,依次用水(3×15mL)、饱和食盐水(4×20mL)洗,用无水硫酸钠干燥有机相,减压蒸干,粗产品经柱层析(石油醚/乙酸乙酯=4:1)得白色固体即化合物28,741.1mg。产率为74%。
1H NMR(400MHz,CDCl3)δ:6.72(d,J=7.9Hz,1H),6.60(d,J=7.9Hz,1H),6.05(s,1H),3.54–3.40(m,2H),3.19(dd,J=12.4,5.2Hz,1H),3.03(t,J=6.6Hz,1H),2.24-2.19(m,4H),2.12(dd,J=6.6,2.6Hz,1H),2.09–2.05(m,1H),2.00(dd,J=11.4,3.6Hz,1H),1.93(d,J=18.8Hz,1H),1.73–1.58(m,2H),1.36(qd,J=12.8,5.9Hz,1H),1.12(s,3H).13CNMR(100MHz,CDCl3)δ:221.48,153.40,153.37,142.60,136.17,136.13,121.29,121.27,120.66,114.11,50.89,50.83,50.48,50.39,48.75,48.13,44.42,37.01,22.70,19.93,12.19.
化合物C56的制备:
将化合物28(50mg,0.16mmol)、苯乙炔(32.6mg,0.32mmol)、醋酸铜(48.0mg,0.24mmol)、抗坏血酸钠(63.4mg,0.32mmol)、水(2mL)和四氢呋喃(8mL)混合,反应12h,反应结束,加入8mL水,用乙酸乙酯(3×24mL)萃取,合并有机相,依次用水(6mL)、饱和食盐水(2×10mL)洗,用无水硫酸钠干燥,减压蒸干,经柱层析(石油醚/乙酸乙酯=3:1)得白色固体即化合物C56,46.4mg,收率70%,熔点:151-154℃。
IRνmax(cm-1):3367,2925,2867,1736,1599,1458,1361,1265,1054,972,912,817,765,729,695.HRMS(ESI)m/z calculated for C26H28O2N3[M+H]+:414.2176,found:414.2177.1H NMR(400MHz,CDCl3)δ:7.73(dd,J=7.1,1.7Hz,2H),7.43-7.35(m,3H),7.33-7.29(m,1H),7.23(s,1H),6.72(s,2H),4.70(dd,J=14.0,6.9Hz,1H),4.45(dd,J=14.0,6.3Hz,1H),3.52(t,J=6.6Hz,1H),2.93(dd,J=12.2,5.2Hz,1H),2.28-2.01(m,3H),1.95(s,1H),1.90(s,3H),1.75(d,J=11.4Hz,1H),1.57(ddt,J=25.5,12.8,6.3Hz,2H),1.32(qd,J=16.0,14.4,4.1Hz,1H),1.02(s,3H).13C NMR(100MHz,CDCl3)δ:220.19,153.91,147.87,142.25,135.84,130.18,128.98,128.42,125.83,121.71,121.02,120.71,114.50,51.22,50.89,50.71,49.78,48.66,47.97,43.49,36.86,22.72,19.83,11.83.
化合物C57的制备:
制备方法同化合物C56,将苯乙炔改成4-甲氧基苯乙炔,经柱层析(石油醚/乙酸乙酯=3:1)得白色固体即化合物C57,56.1mg,收率79%。熔点:165-167℃。
IRνmax(cm-1):3383,2925,1738,1661,1617,1562,1500,1457,1362,1250,1175,1031,835,726,534.HRMS(ESI)m/z calculated for C27H30O3N3[M+H]+:444.2282,found:444.2281.1H NMR(400MHz,CDCl3)δ:7.65(d,J=8.7Hz,2H),7.31(s,1H),7.15(s,1H),6.90(d,J=8.8Hz,2H),6.72(s,2H),4.68(dd,J=14.0,7.0Hz,1H),4.43(dd,J=14.0,6.3Hz,1H),3.80(s,3H),3.51(t,J=6.6Hz,1H),2.93(dd,J=12.7,5.6Hz,1H),2.28-2.01(m,3H),1.92(d,J=20.8Hz,4H),1.74(d,J=11.3Hz,1H),1.66-1.50(m,2H),1.32(ddd,J=25.6,12.8,5.6Hz,1H),1.02(s,3H).13C NMR(100MHz,CDCl3)δ:220.04,159.77,153.93,147.76,142.35,135.90,127.17,122.96,121.72,121.04,119.89,114.48,114.40,55.43,51.24,50.95,50.70,49.73,48.69,48.01,43.52,36.88,22.74,19.85,11.83.
化合物C58的制备:
制备方法同化合物C56,将苯乙炔改成2-乙炔基吡啶,经柱层析(石油醚/乙酸乙酯=1:1)得白色固体即化合物C58,40.5mg,收率61%。熔点:142-145℃。
IRνmax(cm-1):3377,2925,2867,1736,1600,1473,1422,1365,1266,1096,1052,911,785,731.HRMS(ESI)m/z calculated for C25H27O2N4[M+H]+:415.2129,found:415.2130.1H NMR(400MHz,CDCl3)δ:8.67–8.40(m,1H),8.33–8.11(m,1H),7.99(s,1H),7.87–7.69(m,2H),7.26–7.21(m,1H),6.71(d,J=7.9Hz,1H),6.64(d,J=7.9Hz,1H),4.74(dd,J=14.1,7.6Hz,1H),4.49(dd,J=14.1,5.3Hz,1H),3.54(dd,J=7.6,5.4Hz,1H),3.02–2.91(m,1H),2.26–2.06(m,3H),1.99(s,3H),1.91(d,J=18.8Hz,1H),1.70(d,J=11.4Hz,1H),1.65–1.48(m,2H),1.34(qd,J=12.7,5.9Hz,1H),1.00(s,3H).13C NMR(100MHz,CDCl3)δ:219.73,154.13,149.88,149.15,147.97,142.10,137.57,135.81,123.26,123.02,121.71,121.02,120.72,114.56,51.20,51.10,50.70,49.75,48.81,48.05,43.56,36.87,22.76,19.87,11.99。
化合物C59的制备:
制备方法同化合物C56,将苯乙炔改成4-三氟甲基苯乙炔,经柱层析(石油醚/乙酸乙酯=3:1)得白色固体即化合物C59,60.2mg,收率78%。熔点:148-152℃。
IRνmax(cm-1):3412,2927,1736,1622,1458,1326,1166,1124,1064,849,728,598.HRMS(ESI)m/z calculated for C27H27O2N3F3[M+H]+:482.2050,found:482.2053.1HNMR(400MHz,CDCl3)δ:7.83(d,J=8.1Hz,2H),7.62(d,J=8.1Hz,2H),7.43(s,1H),6.82-6.62(m,3H),4.74(dd,J=14.0,6.8Hz,1H),4.49(dd,J=14.0,6.4Hz,1H),3.53(t,J=6.6Hz,1H),2.92(dd,J=12.2,5.2Hz,1H),2.30-2.03(m,3H),1.94(d,J=19.6Hz,1H),1.87(s,3H),1.79(d,J=10.9Hz,1H),1.59(ddt,J=25.5,12.8,6.3Hz,2H),1.33(qd,J=12.8,5.7Hz,1H),1.04(s,3H).13C NMR(100MHz,CDCl3)δ:220.07,153.79,146.56,142.23,136.05,133.70,130.68,130.36,130.04,129.71,126.00,125.97,125.92,125.46,122.76,121.67,121.44,121.15,114.53,51.30,50.92,50.78,49.93,48.68,48.05,43.56,36.88,22.73,19.83,11.80.
化合物C60的制备:
制备方法同化合物C56,将苯乙炔改成4-甲基苯乙炔,经柱层析(石油醚/乙酸乙酯=3:1)得白色固体即化合物C60,52.0mg,收率76%。熔点:156-158℃。
IRνmax(cm-1):3374,2925,2867,1736,1599,1499,1456,1361,1266,1223,1054,910,818,727,518.HRMS(ESI)m/z calculated for C27H30O2N3[M+H]+:428.2333,found:428.2333.1H NMR(400MHz,CDCl3)δ:7.63(d,J=7.9Hz,2H),7.37(s,1H),7.19(d,J=7.9Hz,2H),6.72(s,2H),4.69(dd,J=14.0,7.0Hz,1H),4.44(dd,J=14.0,6.3Hz,1H),3.52(t,J=6.6Hz,1H),2.93(dd,J=12.2,5.2Hz,1H),2.35(s,3H),2.25–1.98(m,4H),1.96(d,J=10.1Hz,1H),1.90(s,3H),1.74(d,J=11.3Hz,1H),1.58(dtd,J=17.8,12.8,5.1Hz,2H),1.43–1.24(m,1H),1.02(s,3H).13C NMR(100MHz,CDCl3)δ:220.14,153.91,147.95,142.29,138.31,135.86,129.65,127.37,125.75,121.70,121.01,120.35,114.49,51.23,50.92,50.70,49.75,48.68,47.98,43.50,36.87,22.73,21.36,19.84,11.82.
化合物C61的制备:
制备方法同化合物C56,将苯乙炔改成4-氯苯乙炔,经柱层析(石油醚/乙酸乙酯=3:1)得白色固体即化合物C61,53.8mg,收率75%。熔点:153-156℃。IRνmax(cm-1):3397,2925,2868,1735,1600,1484,1456,1361,1266,1093,1054,973,835,730,517.HRMS(ESI)m/z calculated for C26H27O2N3Cl[M+H]+:448.1786,found:448.1788.1H NMR(400MHz,CDCl3)δ:7.78-7.56(m,2H),7.38-7.31(m,3H),6.86(s,1H),6.79-6.60(m,2H),4.71(dd,J=14.0,6.8Hz,1H),4.45(dd,J=14.0,6.4Hz,1H),3.51(t,J=6.6Hz,1H),2.93(dt,J=12.2,6.2Hz,1H),2.19-2.05(m,3H),1.93(d,J=18.9Hz,1H),1.86(s,3H),1.77(d,J=11.3Hz,1H),1.58(ddt,J=25.5,12.8,6.4Hz,2H),1.43-1.25(m,1H),1.03(s,3H).13C NMR(100MHz,CDCl3)δ:220.04,153.79,146.87,142.26,135.99,134.15,129.18,128.75,127.08,121.67,121.10,120.74,114.50,51.27,50.92,50.74,49.85,48.67,48.03,43.54,36.88,22.73,19.85,11.80.
化合物C62的制备:
制备方法同化合物C56,将苯乙炔改成4-氟苯乙炔,经柱层析(石油醚/乙酸乙酯=3:1)得白色固体即化合物C62,47.7mg,收率69%。熔点:146-147℃。
IRνmax(cm-1):3393,2926,2868,1736,1599,1561,1498,1458,1362,1266,1224,1157,1097,1054,841,815,728,526.HRMS(ESI)m/z calculated for C26H27O2N3F[M+H]+:432.2082,found:432.2084.1H NMR(400MHz,CDCl3)δ:7.78-7.55(m,2H),7.33(s,1H),7.06(t,J=8.6Hz,2H),6.85(s,1H),6.79-6.61(m,2H),4.72(dd,J=14.0,6.9Hz,1H),4.46(dd,J=14.0,6.4Hz,1H),3.52(t,J=6.6Hz,1H),2.99-2.90(m,1H),2.29-2.01(m,3H),1.94(d,J=19.0Hz,1H),1.88(s,3H),1.77(d,J=11.3Hz,1H),1.59(ddt,J=25.4,12.8,6.3Hz,2H),1.41-1.22(m,1H),1.03(s,3H).13C NMR(101MHz,CDCl3)δ:220.01,164.02,161.56,153.81,147.08,142.31,136.01,127.65,127.57,126.51,126.48,121.67,121.10,120.42,116.09,115.87,114.49,51.28,50.95,50.75,49.82,48.69,48.05,43.56,36.89,22.75,19.86,11.81.
效果实施例
本发明的活性测试采用了MTS的检测方法,MTS为MTT类似物,全称为3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-sulfopheny)-2H-tetrazolium。此方法通过活细胞线粒体中琥珀酸脱氢酶能够代谢还原MTS,生成可溶性的甲臜(Formazan)化合物,该化合物的光密度OD(490nM)值与活细胞数目成正比,通过光密度OD的测定值来衡量化合物的抗肿瘤活性。本发明挑选五种肿瘤细胞:HL-60,A549,SMMC-7721,MCF-7和SW480进行实验,检测以顺铂和紫杉醇作为阳性对照。化合物的IC50值通过浓度效应生长曲线计算确定。
MTS具体的检测方法参照:
[1]D.K.Kim,D.H.Ryu,J.Y.Lee,N.Lee,Y.W.Kim,J.S.Kim,K.Chang,G.J.Im,T.K.Kim and W.S.Choi,Journal of medicinal chemistry,2001,44,1594-1602;
[2]R.Cao,Q.Chen,X.Hou,H.Chen,H.Guan,Y.Ma,W.Peng and A.Xu,Bioorganic&medicinal chemistry,2004,12,4613-4623。
部分化合物按照MTT方法进行了白血病、肝癌、肺癌、乳腺癌和结肠癌5种细胞株的抗肿瘤细胞毒活性筛选,其半数抑制剂量(IC50值,μM)测定结果与已商品化的抗癌药物——顺铂(DDP)和紫杉醇相比较于下表1和表2中。
表1化合物C1-C32,C36,B1,B2的细胞毒活性数据
表2化合物C33-C62,B3的细胞毒活性数据
以上活性数据显示化合物C21,C28,C30,C31具有一般的体外细胞毒活性。化合物C33,C34,C35,C37,C38,C39对乳腺癌细胞(MCF-7)具有显著的体外细胞毒活性。化合物C40,C41,C42,C43,C44,C45,C46,C47对结肠癌细胞(SW480)具有显著的体外细胞毒活性。化合物C45,C46,C47具有广谱的体外抗癌细胞毒活性。
化合物B1、B2和B3的结构如下所示:
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。
Claims (13)
3.如权利要求1或2所述的类赤霉素化合物、其互变异构体、光学异构体或药学上可接受的盐,其特征在于,
所述卤素为氟、氯、溴或碘;
和/或,所述C1-C6的烷基为C1-C4的烷基;
和/或,所述卤素取代的C1-C6的烷基中的卤素取代基的个数为一个或多个;
和/或,所述C1-C6的烷氧基为C1-C4的烷氧基。
4.如权利要求1或2所述的类赤霉素化合物、其互变异构体、光学异构体或药学上可接受的盐,其特征在于,
所述C1-C6的烷基为甲基,乙基,丙基,异丙基或正丁基;
和/或,所述卤素取代的C1-C6的烷基中的卤素取代基的个数为一个或多个;所述卤素为氟;
和/或,所述C1-C6的烷氧基为甲氧基,乙氧基或丙氧基。
5.如权利要求1所述的类赤霉素化合物、其互变异构体、光学异构体或药学上可接受的盐,其特征在于,
当所述R1为卤素时,所述R为卤素,或者卤素取代的C1-C6的烷基;
当所述R1为H时,所述R为卤素取代的C1-C6的烷基。
6.如权利要求2所述的类赤霉素化合物、其互变异构体、光学异构体或药学上可接受的盐,其特征在于,所述R2为OH或OTs。
10.一种药物组合物,其特征在于,包括治疗有效量的如权利要求1-7任一项所述的类赤霉素化合物、其互变异构体、光学异构体或药学上可接受的盐,和一种或多种药学上可接受的载体或赋形剂。
11.如权利要求1-7任一项所述的类赤霉素化合物、其互变异构体、光学异构体或药学上可接受的盐在制备治疗和/或预防抗肿瘤药物中的应用。
12.如权利要求11所述的应用中,所述抗肿瘤药物为抗乳腺癌药物和/或抗肠癌药物。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810273045.4A CN110317179B (zh) | 2018-03-29 | 2018-03-29 | 类赤霉素化合物、其制备方法、药物组合物及应用及其中间体 |
PCT/CN2019/078805 WO2019184772A1 (zh) | 2018-03-29 | 2019-03-20 | 类赤霉素化合物、其制备方法、药物组合物及应用及其中间体 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810273045.4A CN110317179B (zh) | 2018-03-29 | 2018-03-29 | 类赤霉素化合物、其制备方法、药物组合物及应用及其中间体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110317179A CN110317179A (zh) | 2019-10-11 |
CN110317179B true CN110317179B (zh) | 2023-01-24 |
Family
ID=68059274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810273045.4A Active CN110317179B (zh) | 2018-03-29 | 2018-03-29 | 类赤霉素化合物、其制备方法、药物组合物及应用及其中间体 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110317179B (zh) |
WO (1) | WO2019184772A1 (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1560044A (zh) * | 2004-02-27 | 2005-01-05 | 云南大学 | 3,15-二羰基赤霉酸类化合物及其酯和盐 |
WO2010062372A2 (en) * | 2008-11-03 | 2010-06-03 | President And Fellows Of Harvard College | Methods for modulating nf-kb using gibberellins |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR051597A1 (es) * | 2004-11-01 | 2007-01-24 | Merck & Co Inc | Moduladores de los receptores de estrogeno |
CN102108075A (zh) * | 2009-12-28 | 2011-06-29 | 中国药科大学 | 由赤霉素ga3合成新颖衍生物的合成方法及其应用 |
WO2013142873A2 (en) * | 2012-03-23 | 2013-09-26 | The Board Of Trustees Of The University Of Illinois | Complex and structurally diverse compounds |
-
2018
- 2018-03-29 CN CN201810273045.4A patent/CN110317179B/zh active Active
-
2019
- 2019-03-20 WO PCT/CN2019/078805 patent/WO2019184772A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1560044A (zh) * | 2004-02-27 | 2005-01-05 | 云南大学 | 3,15-二羰基赤霉酸类化合物及其酯和盐 |
WO2010062372A2 (en) * | 2008-11-03 | 2010-06-03 | President And Fellows Of Harvard College | Methods for modulating nf-kb using gibberellins |
Non-Patent Citations (1)
Title |
---|
<SOLID STATE PHOTOAROMATIZATIOIV OF 3-KEY!O-GIBBERELLIB A3>;G. Adam and B. Voigt;<Tetrahedron Letters>;19711027(第48期);全文 * |
Also Published As
Publication number | Publication date |
---|---|
WO2019184772A1 (zh) | 2019-10-03 |
CN110317179A (zh) | 2019-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105992759B (zh) | 1,2-萘醌的衍生物及其制备方法 | |
JPH01168689A (ja) | K−252誘導体 | |
KR102266680B1 (ko) | 벨리노스테트의 다형태 및 이의 제조 방법 | |
CN111961034A (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
RU2286993C2 (ru) | 3,7-диазабицикло[3.3.1]-препараты как антиаритмические соединения | |
JP6779318B2 (ja) | 抗転移性2H‐セレノフェノ[3,2‐h]クロメン、それらの合成、および同薬剤の使用方法 | |
CN115785068A (zh) | Kif18a抑制剂 | |
JP6298768B2 (ja) | 7−置換ハンファンギチンb誘導体、その調製方法及び使用 | |
CA2690349A1 (fr) | Derives de 7 -alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique | |
CN106414468B (zh) | 富马酸-co-释放分子杂合物、其在治疗炎性或心血管疾病中的用途和其制备方法 | |
JPS62120388A (ja) | Sf−2370物質ハロゲン化誘導体とその製造法 | |
KR100281867B1 (ko) | 3-(비스-치환페닐메틸렌)옥신돌유도체 | |
CN110317179B (zh) | 类赤霉素化合物、其制备方法、药物组合物及应用及其中间体 | |
KR950011748B1 (ko) | 술펜아미드 유도체 및 그의 제조방법 | |
CN115772159A (zh) | Kif18a抑制剂 | |
JP7244487B2 (ja) | ステロイド系誘導体fxrアゴニストの結晶又は非晶質、その製造方法及び使用 | |
WO2014032398A1 (zh) | 哒嗪酮类化合物、其制备方法、药物组合物及其用途 | |
AU2021372796A1 (en) | New crystalline forms of a kras g12c inhibitor compound | |
JPS6024102B2 (ja) | 5−フルオロウラシル誘導体の製法 | |
CN115109083B (zh) | Pyridostatin类化合物及其制备方法、应用、药物组合物 | |
JPH07242670A (ja) | ピロロ[3,2−e]ピラゾロ[1,5−a]ピリミジン誘導体及びこれを含有する循環器系疾患治療剤 | |
CN114213501B (zh) | A环并异噁唑环常春藤皂苷元c-23位含氮杂环衍生物及其制备方法 | |
JP2546841B2 (ja) | 新規なイミダゾ〔4,5−b〕ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤 | |
US5420117A (en) | 5-substituted uridine derivatives | |
CN115160257A (zh) | 一种姜黄素衍生物的合成制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |